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To my family
”Målet är ingenting,
vägen är allt.
Målet är vägen.”
Robert Broberg
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ABSTRACT
Coronary artery disease (CAD) is a major cause of morbidity and death in the world today. The underlying
process, atherosclerosis, is caused by lipid accumulation and inflammatory processes within the intimal
layer of the vessel wall. Stable CAD is characterized by gradually expanding atherosclerotic plaques that
narrow the lumen and, by restricting the blood flow, give rise to ischemic symptoms. Acute coronary
syndromes (ACS) are usually caused by vulnerable plaques, which rupture or erode, thus initiating thrombus
formation that suddenly impairs the blood flow and may cause acute myocardial infarction (MI).
Inflammation is now considered to be an important feature of both atherosclerosis and atherothrombotic
complications. Inflammatory cells, such as macrophages, T-cells and mast cells, are present in the
atherosclerotic tissue and interact with the cells present in the vascular wall.
Matrix metalloproteinases (MMPs), a family of more than 20 zinc- and calcium-dependent proteases,
are capable of degrading extracellular matrix components. MMPs are involved in both the expansion of
atherosclerotic plaques and the weakening of the fibrous cap, thus contributing to the development of
vulnerable plaques. Inflammatory cells are suggested to be the major source of MMPs.
The aim of this thesis was to evaluate the roles of MMP-3 and MMP-1 in CAD and MI, and how the
expression of these MMPs may be modulated by inflammation. This was addressed by genetic analyses of
known and novel polymorphisms in the MMP-3 and MMP-1 genes, biochemical analyses of circulating
MMP-3, MMP-1, and various cytokines, and angiographic analyses of the extent and severity of CAD. The
individual studies were conducted in three different cohorts: i) the Stockholm Coronary Artery Risk Factor
(SCARF) study, a case-control study of 387 postinfarction patients and 387 healthy control persons, ii) 164
patients from the Thrombolysis and REOCclusion (TREOC) study, a longitudinal cohort study of patients
with ST-elevation MI, and iii) 1177 patients from the Southampton Atherosclerosis Study (SAS) with
significant CAD as assessed by coronary angiography.
Serum MMP-3 concentrations were lower in postinfarction patients compared with control subjects.
Also, serum concentrations of MMP-3 were lower in the acute stage of MI (within 48 hours) than at the
three months follow-up visit. Plasma MMP-1 concentrations did not differ between postinfarction patients
and controls.
The MMP-3 -1612 5A/6A promoter polymorphism markedly influenced the serum MMP-3 con-
centrations in two different cohorts of postinfarction patients and in healthy controls. Serum MMP-3
concentrations increased with the number of 6A-alleles. Furthermore, the serum MMP-3 concentration
increased with the number of diseased major coronary arteries, as evaluated by coronary angiography.
Women had substantially lower serum MMP-3 concentrations compared with men in the SCARF
and the TREOC study cohorts. In addition, plasma MMP-1 concentrations were lower in women in the
SCARF study.
Studies of the MMP-1 gene revealed a haplotype effect of the MMP-1 –519 A/G and –340 C/T
promoter polymorphisms on risk of MI. Compared with the A
-519
-T
-340
 haplotype, both the A
-519
-C
-340
 and
G
-519
-T
-340
 haplotypes showed a protective effect against MI whereas the G
-519
-C
-340
 haplotype was associated
with an increased risk of MI. Functional studies of gene expression demonstrated a lower promoter activity
of the A
-519
-C
-340
 and G
-519
-T
-340
 haplotypes than of the A
-519
-T
-340
 haplotype. Also, mRNA levels in
atherosclerotic plaques were significantly lower in plaques retrieved from carriers of the A
-519
-C
-340
 and
G
-519
-T
-340
 haplotypes than from carriers of the A
-519
-T
-340
 haplotype.
Plasma concentrations of interleukin-2 (IL-2), IL-6, IL-8, and tumour necrosis factor-α were higher
in postinfarction patients than in controls. Furthermore, there was a difference between MMP-3 and MMP-
1 concentrations as regards their respective correlations with several circulating inflammatory cytokines.
Correlations were found for MMP-1, but not for MMP-3.
In conclusion, the results presented in this thesis reinforce the novel alternative hypothesis of divergent
effects of different MMPs in atherosclerosis and CAD. Inflammation is suggested to exert a stronger influence
on MMP-1 than on MMP-3. Reduced MMP-3 concentration seems to be associated with MI, whereas
increased concentration may promote progression of stable CAD.
Keywords: Myocardial infarction, matrix metalloproteinases, inflammation, polymorphism, haplotype, cytokines, gender
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Cardiovascular disease (CVD) is the major cause
of morbidity and death in the world today. One
third of all deaths worldwide are due to different
manifestations of CVD, mainly ischemic heart
disease, stroke and peripheral artery disease1. The
pathophysiology of atherosclerosis and arterial
thrombosis is the common denominator of most
aspects of CVD.
INTRODUCTION
The arterial vessel wall
The unaffected human artery consists of three dif-
ferent layers2,3. Innermost is the intima with a
monolayer of endothelial cells protecting the
subendothelial proteoglycan layer from the blood
stream, thus providing a barrier preventing pro-
thrombotic molecules within the intima from
coming into contact with platelets and coagulation
factors in the blood. The outer boundary of the in-
tima is the internal elastic lamina. The intima
contains widely spaced single smooth muscle cells
(SMCs) of both synthetic and contractile pheno-
types. Synthetic SMCs are capable of synthesizing
matrix components, including collagen, and of rem-
oval of lipoproteins. Contractile SMCs constitute
the ”classical” phenotype, rich in myofilament and
responding to mediators of the vascular tone. The
matrix of the intima consists of collagens, pro-
teoglycans, elastin, fibronectin and laminin.
The media, delimited by the internal and external
elastic laminae, is inhabited mainly by contractile
SMCs in spiralling layers, forming the muscular
wall of the artery. The outermost layer, the adventi-
tia, contains collagen fibrils, elastic fibres, fibro-
blasts and also some SMCs. The adventitia is provi-
ding nutrition to the vessel wall via the vasa
vasorum, as well as the innervation of the artery.
Atherosclerosis
The pathological process of atherosclerosis takes
place within the intima and involves modified lip-
ids, inflammatory cells, SMCs and endothelial
cells. Decades ago, atherosclerosis was conside-
red a degenerative process caused by lipid over-
loading2. In the past twenty-five years, evidence
has accumulated that inflammatory processes are
crucial for initiation and progression of athero-
sclerosis, rupture of the fibrous cap and thrombotic
complications leading to ischemia of the end or-
gan, i.e. myocardial infarction (MI) in the case of
coronary atherosclerosis4,5.
Initiation and progression of lesions
In the initiation of atherosclerotic lesion formation
lipoproteins infiltrate and are retained in the in-
tima of the vessel wall4,5. Low density lipoproteins
(LDLs) are then subjected to oxidative modi-
fication, which render them capable of activating
endothelial cells to express adhesion molecules,
most importantly vascular cell adhesion molecule-
1 (VCAM-1). The adhesion molecules attract
inflammatory cells, mainly monocytes and T-
lymphocytes, from the blood stream and make them
rolling over the endothelial surface. Eventually they
migrate into the intimal layer in response to chemo-
kines. These are specific for each cell type, e.g.
monocyte chemoattractant protein-1 (MCP-1) for
monocytes but also for T- and B-cells. Inside the
vessel wall, monocytes transform into macrophages
and phagocyte the modified LDL particles.
Cholesterol accumulates and the macrophages
evolve into foam cells. At this stage the lesions
form so-called ”fatty streaks” which are present in
human arteries already at an early age6. Later on,
SMCs migrate into the intima and proliferate, thus
constituting a substantial portion of the fibrous cap
and producing ECM constituents. The activated
macrophages secrete pro-inflammatory cytokines
as well as matrix metalloproteinases (MMPs) and
tissue factor, all substances that promote progres-
sion of atherosclerosis into advanced lesions,
plaque rupture and thrombus formation4,5
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The vulnerable plaque
The concept of the vulnerable plaque, a plaque
prone to rupture, has been established since almost
twenty years. The vulnerable plaque is charac-
terized by a large, lipid-rich core, surrounded by
clusters of macrophages and other inflammatory
cells, and an overlying thin fibrous cap, with a
reduced number of SMCs and a decreased amount
of collagen7-9. The combination of an acellular lipid
core, accumulation of macrophages in the shoulder
region and a thin, collagen-poor fibrous cap ma-
kes the plaque less resistant to the mechanical forces
of the blood stream. The fibrous cap can no longer
resist the forces of the flowing blood and eventually
it will break. As the fibrous cap ruptures, the
extremely thrombogenic lipid-rich core is exposed
to the blood stream, attracting platelets and coa-
gulation factors to the site and thus initiating
thrombus formation8.
Inflammatory cytokines in atherosclerosis
The inflammatory cytokines are important
mediators of the progression of atherosclerotic
lesions. The vulnerable plaque is rich in inflam-
matory cells, such as T-lymphocytes producing the
pro-inflammatory cytokines tumour necrosis
factor-α (TNF-α), interferon-γ  (IFN-γ ) and CD40
ligand, macrophages and foam cells producing
interleukin-1 (IL-1), IL-6, IL-8, IL-18, TNF-α, INF-
γ , tissue factor and MMPs5,10. All these cytokines
amplify the inflammatory cascade. In addition,
neutrophils and mast cells are present in the
vulnerable plaque. Neutrophils secrete neutrophil
elastase and neutrophil collagenase (MMP-8) and
mast cells produce serine proteases capable of
activating MMPs5,11.
T-cells differentiate further into T-helper1- (Th1-),
Th2- or regulatory T-cells, the Th1-cells being the
dominating T-cell type in atherosclerosis4. Th1-cells
are the main source of IFN-γ  and TNF-α. IFN-γ
activates macrophages and endothelial cells, and
decreases SMC and endothelial cell proliferation,
SMC differentiation and SMC collagen production,
thus exerting a pro-atherogenic effect4. In addition
to Th1-cells, IFN-γ  can be secreted by macrophages
and cells of the vascular wall under the stimulation
of other cytokines12. TNF-α, also a pro-atherogenic
cytokine, is produced by Th1-cells and macro-
phages.
In a study of procollagen I and III gene expression
in cultured vascular SMCs, transforming growth
factor-β (TGF-β) and platelet-derived growth
factor (PDGF) were shown to increase messenger
ribo-nucleic acid (mRNA) expression whereas
IFN-γ  decreased mRNA expression and also wiped
out the increasing effect of TGF-β and PDGF when
the cells were co-cultured with IFN-γ , TGF-β and
PDGF, respectively13.
IL-1, produced by macrophages and SMCs, may
contribute to recruitment and activation of leuko-
cytes and platelets, regulation of cell growth,
proliferation and migration of SMCs14,15.
IL-6 is a potent cytokine produced by a wide range
of cells including vascular and inflammatory cells.
IL-6 stimulates macrophage activity and proli-
feration of SMCs, and induces acute phase protein
production in the liver16. Also, IL-6 regulates the
expression of IL-1β and TNF-α by endothelial
cells.
IL-8 has more of chemokine properties, as it can
attract leukocytes and enhances the adhesion of
monocytes to the endothelium. In addition, it can
promote angiogenesis in atherosclerotic tissue10.
Cytokines produced by Th2-cells include IL-10 and
IL-4. IL-4 stimulates antibody production and
activates B-cells and mast cells in atherosclerosis,
and may be considered pro-atherogenic4. Regula-
tory T-cells, together with Th2-cells and macro-
phages, are the source of the anti-inflammatory
cytokines IL-10 and TGF-β. IL-10 inhibits T-cell
and macrophage production of other cytokines,
including INF-γ , and appears to have atheropro-
tective properties as IL-10 deficient mice develop
larger atherosclerotic lesions than wild type mice,
while transgenic mice overexpressing IL-10 show
smaller atherosclerotic lesions17. TGF-β is thought
to be atheroprotective through T-cell inhibition4.
Circulating levels of cytokines
Several studies assessing the risk and/or severity
of coronary artery disease (CAD) associated with
different inflammatory markers have almost con-
sistently shown modestly elevated levels of C-
reactive protein (CRP), IL-1, IL-2 and IL-6 to be
harmful, whereas the studies of TNF-α are fewer
and their results more divergent18.
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Plasma levels of IL-8 were higher in men with
unstable CAD than in men with stable CAD or
healthy controls22. In an Italian study of stable and
unstable CAD, the concentrations of IL-2 were
elevated in both CAD groups whereas IL-6
concentration was elevated only in the unstable
CAD group as compared with the control group23.
In contrast, plasma IL-10 concentrations did not
differ among the different groups. These diverging
results were all except one21 obtained in small
studies with less than 120 participants.
The studies on IL-6 are more comprehensive and
uniform. Increased IL-6 levels have been shown
to predict future cardiovascular events in healthy
individuals of both genders24-26. The plasma
concentration of IL-6 at admission for MI was
shown to be an independent prognostic factor,
predicting death or new MI, after ST-elevation MI
(STEMI)27, whereas the CRP level was not28.
Evaluating circulating IL-6 concentrations has been
proposed for screening patients at risk of acute
coronary syndrome (ACS)16.
Coronary artery disease
CAD is the leading cause of death worldwide. In
2002, 12.6% of all deaths were caused by ischemic
heart disease, the consequence of CAD. In Sweden,
30% of male and 23% of female deaths were due
to CAD in year 2002, but numbers are decreasing
possibly as a consequence of smoking cessation
and lower blood pressure and cholesterol levels in
the community (www.socialstyrelsen.se, Folk-
hälsorapport 2005). One year mortality after MI
in Sweden in 2003 was 5% for patients below 60
years of age, 9.9% between 60-70 years, 21% for
those aged 70-80 and approximately 35% over the
age of 8029.
Well-established risk factors for CAD include age,
male gender, smoking, hypercholesterolemia, dia-
betes and hypertension. These risk factors do not
explain all cases of MI, and additional factors may
play a role in the complex interaction between
genetic predisposition and environmental in-
fluences.
Stable angina pectoris
In stable angina pectoris, atherosclerotic plaques
are slowly growing inwards, gradually impairing
the lumen and blood flow. The patient experiences
chest pain during exercise due to myocardial
ischemia when the oxygen demand exceeds the
oxygen supply. The chest pain usually subsides at
rest, and returns with new exertion. Treatment aims
at relieving symptoms and preventing MI, which
can be achieved by three different approaches: i)
by medications which reduce the oxygen demand
or enhance blood flow, e.g. betablocking agents
and vasodilators, or reduce the progression of
atherosclerosis, e.g. lipid lowering compounds, ii)
by percutaneous coronary intervention (PCI)
aiming at restoring the blood flow by mechanically
reducing the lumen restrictions caused by the
plaques, and iii) by coronary artery bypass graf-
ting (CABG), an open heart surgery procedure
where the stenosed coronary arteries are by-pas-
sed using arterial or saphenous vein grafts2.
Acute coronary syndrome
The pathophysiologic event precipitating ACS, i.e.
unstable angina and MI, is thought to be thrombosis
superimposed on the atherosclerotic plaque. ACS
not infrequently seems to come out of a clear sky,
as the atherosclerotic plaque may not impair blood
flow as long as it not significantly decreases the
lumen. However, when a thrombus occurs intra-
luminally it may cause impaired blood flow at rest
or even total occlusion of the vessel leading to
STEMI. Four different pathological entities have
been recognized to cause ACS: i) plaque rupture is
by far the most common and best defined cause of
intraluminal thrombosis underlying nearly three
quarters of all instances of fatal coronary throm-
bosis; ii) erosion of the endothelial layer exposing
thrombogenic molecules; iii) erosion of calcium
nodule; and iv) intraplaque haemorrhage arising
from the microvasculature of the plaque itself30.
Serum concentrations of TNF-α and IL-10 were
higher in CAD patients than in controls, with no
difference between stable and unstable CAD,
whereas IL-2 was increased in unstable patients
only as compared to controls19. In another study
with a similar design plasma concentrations of
TNF-α but not of IL-10 were elevated in CAD
patients as compared to controls20. A third similar
case-control study failed to detect differences
between the groups in TNF-α levels whereas the
IL-6 concentration was increased in CAD patients
compared with controls21.
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Treatment for ACS is mainly aiming at reducing
thrombus formation, thereby reducing the risk of
propagation to total occlusion. In STEMI, where
the affected artery is already occluded, restoration
of blood flow by revascularization, PCI or throm-
bolysis, is the primary aim. In unstable angina and
non-STEMI efforts are directed towards inhibition
of thrombus propagation by blunting platelet acti-
vity and the coagulation cascade. This is achieved
by aspirin, adenosine diphosphate-receptor anta-
gonists and glucoprotein IIb/IIIa-inhibitors and with
PCI and stenting of the culprit lesion2.
Matrix metabolism in the fibrous cap
Synthesis and degradation of extracellular matrix
(ECM) components are determinants of the fibrous
cap composition and strength. SMCs are the main
providers of collagen precursors, and the collagen
synthesis is dependent on both the amount of SMCs
and their synthesizing capacity. TGF-β and PDGF
enhance the collagen synthesis in SMCs whereas
IFN-γ  markedly decreases this capacity9. IFN-γ  may
also inhibit SMC proliferation and promote SMC
apoptosis9. Degradation of collagen and elastin is
enhanced by different proteases released from most
of the vascular cells, but most profoundly from
macrophages. TNF-α, IL-1 and MCP-1 are cyto-
kines known to stimulate protease secretion from
vascular cells9,10.
Proteases are enzymes capable of degrading pro-
teins into amino acids by cleavage of peptide bonds.
The proteases are subgrouped according to the
active residue of the catalytic site of the enzyme
into serine proteases, cysteine proteases, aspartic
proteases and metalloproteinases. The metallo-
proteinases are further divided into metallocarboxi-
peptidases and metalloendopeptidases. The prefix
”metallo-” indicates that the protease is dependent
on a metal ion, i.e. Zn2+, at its active site.
Matrix metalloproteinases (MMPs)
The matrix metalloproteinases (MMPs), a family
of zinc- and calciumdependent proteolytic en-
zymes, are members of the metalloendopeptidases,
and are capable of degrading ECM components of
various tissues, thus being implicated in the degra-
dation of the fibrous cap leading to plaque rupture.
The MMPs are involved in a number of physio-
logical processes encompassing matrix degrada-
tion, such as embryonic development, wound
healing, tissue reabsorption and inflammation31.
The action of different MMPs is implicated in cell
migration, reorganization of tissues, regenerative
processes, neovascularization and tumour spread-
ing31. Generally MMPs are grouped into five
different classes according to their structure and
substrate specificity; these are collagenases, gela-
tinases, stromelysins, membrane-type MMPs (MT-
MMPs) and others (Table 1). In all, there are more
than 20 different MMPs identified in humans32.
The amino acid sequence of different MMPs shows
about 40% homology. The principal structure of
MMPs is composed of three domains; pro-peptide,
catalytic domain and hemopexin-like domain. MT-
MMPs have an additional domain, the trans-
membrane domain.
Regulation of MMP activity
The consequence of MMP activity, i.e. degradation
of structural and matrix molecules, could be
deleterious if it would appear at inappropriate sites
and time points. To prevent such hazardous
incidents the activity of the MMPs is tightly re-
gulated. This regulation takes place at three
different levels; altered gene transcription, extra-
cellular activation of pro-enzymes and inhibition
of activated MMPs by tissue inhibitors of
metalloproteinases (TIMPs). The expression of
MMP genes is known to be influenced by cyto-
kines, growth factors and hormones. For example
IL-1 and TNF-α upregulate transcription, whereas
TGF-β and corticosteroids inhibit MMP ex-
pression33, 34. Activation of the pro-enzymes takes
place extracellularly, and the main activator of
MMPs is plasmin, even though there is some auto-
activation by the MMPs themselves as well as
activation by other proteases like the serine
proteases. The third regulatory level is the inacti-
vation of MMPs by TIMPs. There are four different
TIMPs, TIMP-1 and TIMP-2 being the most
studied forms. They act by an irreversible binding
to the MMP and block the catalytic site33. TIMPs
are often co-expressed with MMPs, probably to
create a local and tightly regulated proteolytic
activity.
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Group MMP Trivial name Substrate
Collagenases MMP-1 Interstitial Collagens I, II, III, VII, VIII and X, MMP-2, MMP-9
collagenase
MMP-8 Neutrophil Collagens I, II, III, V, VII, VIII and X, fibronectin
collagenase
MMP-13 Collagenase-3 Collagens I, II, III and V
Gelatinases MMP-2 Gelatinase A Gelatin, collagens I, IV, V, VII, X, XI and XIV, elastin,
fibronectin, MMP-9, MMP-13
MMP-9 Gelatinase B Gelatin, collagens IV, V, VII, X and XIV, elastin, fibronectin
Stromelysins MMP-3 Stromelysin-1 Collagens III, IV, IX and X, elastin, laminin, proteoglycans,
fibronectin, MMP-1, MMP-7, MMP-8, MMP-9, MMP-13
MMP-10 Stromelysin-2 Collagens III, IV and V, elastin, fibronectin, MMP-1, MMP-8
MMP-11 Stromelysin-3
Membrane type MMP-14 MT1-MMP Collagens I, II and III, fibronectin, laminin vitronectin, MMP-2,
MMP-13
MMP-15 MT2-MMP Fibronectin, laminin, MMP-2
MMP-16 MT3-MMP MMP-2
MMP-17 MT4-MMP
Others MMP-7 Matrilysin-1 Collagens IV and X
MMP-12 Metalloelastase Collagen IV, elastin, fibronectin, vitronectin, laminin
Table 1: The major matrix metalloproteinases (MMPs) and their substrates
Adapted from Beaudeux et al. 2004
MMPs can be expressed by various cells, such as
chondrocytes, myocytes, osteoblasts, and epithelial,
endothelial and inflammatory cells35. In the vascular
wall all major cell types can express MMPs in
response to stimulation. Accordingly, MMP ex-
pression occurs in macrophages, SMCs, endothelial
cells, T-lymphocytes, mast cells and fibroblasts36.
In atherosclerosis, macrophages have been sug-
gested to be the main source of MMP expression.
In an experimental study of gene expression in
THP-1 monocytes undergoing differentiation into
macrophages, MMP-1, MMP-2, MMP-9 and
MMP-14 were upregulated, whereas MMP-17
expression did not change, and other MMPs, in-
cluding MMP-3, were not expressed either before
or after differentiation37. This finding was confir-
med in human primary monocytes and macro-
phages.
MMPs in atherosclerosis
In the normal arterial wall, only MMP-2 is
constitutionally expressed along with TIMP-1 and
TIMP-238. In atherosclerosis, on the other hand,
there is strong evidence for expression of several
MMPs in plaques, including MMP-1, MMP-2,
MMP-3, MMP-9 and MMP-1338-41.
In recent years new technologies to study protein
effects have emerged. Mouse models, using a
knockout strategy (silencing of the gene) or a
transgenic approach (overexpression of the gene),
have proven to be valuable tools to understand the
impact of different proteins on disease develop-
ment42. Mouse models are convenient as the
animals have a relatively short life span. As mice
do not develop atherosclerosis spontaneously,
genetically modified mice strains have been
engineered to get atherosclerotic prone mice. One
common model is the apoE knockout mouse in
which advanced atherosclerotic lesions similar to
those occurring in humans appear. ApoE knockout
mice fed a Western type diet become extremely
hypercholesterolemic and develop atherosclerosis
even more rapidly. However, in general these mice
do not develop plaque rupture followed by throm-
botic complications. Another model of athero-
sclerosis is the LDL-receptor deficient mouse and
a number of transgenic mice expressing human
genes. Unfortunately there is not yet any optimal
model to study spontaneous plaque rupture with
ensuing thrombosis.
Several MMPs have been knocked out without
conclusive findings. Importantly, it is a known
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phenomenon when performing such experiments
that there can be compensatory mechanisms
accounted for by other related molecules. In a study
by Johnson et al. the authors conclude that MMPs
have divergent effects, suggesting MMP-3 and
MMP-9 to be anti-atherogenic, MMP-12 to be pro-
atherogenic and MMP-7 to be indifferent as regards
atherogenesis43.
In a study by Silence et al. the apoE/MMP-3 double
knockout mouse was studied in relation to athero-
sclerosis44. The double knockout mice developed
more severe atherosclerosis, as measured by per-
centage lumen area containing atherosclerotic
plaques, than the single apoE knockout mice. The
plaques of the double knockout mice contained less
macrophages and had a lower lipid, but higher
collagen content. In addition, aneurysms of thoracic
and abdominal aortas were less frequent in the
apoE/MMP-3 double knockout mice than in single
apoE knockout mice. These results were to a large
extent confirmed in the study by Johnson et al.
investigating the brachiocephalic arteries of apoE
deficient mouse strains in which one of the
respective MMP-3, MMP-7, MMP-9 or MMP-12
genes had been knocked out43. In the apoE/MMP-
3 double knockout mice the plaque area was greater,
the number of buried fibrous layers per plaque
(suggesting previous plaque rupture) was higher,
and the content of SMC was lesser, whereas the
content of macrophages did not differ in relation
to the apoE single knockout mice. The same
findings pertained to MMP-9 except that apoE/
MMP-9 double knockout mice also had a higher
content of macrophages in their plaques as
compared to apoE single knockout mice. In apoE/
MMP-7 knockouts there were no differences
except for SMC content, which was higher in
double knockouts as compared to apoE single
knockouts. Finally, in the apoE/MMP-12 double
knockouts the plaque area was smaller, the number
of buried fibrous layers per plaque was lower, the
SMC content higher and the macrophage content
lower than in the apoE single knockout. Deguchi
et al. have studied atherosclerosis in apoE/MMP-
13 deficient mice on an atherogenic diet45. After
10 weeks the double knockout mice and the single
apoE knockout mice had similar plaque area and
plaque content of macrophages and SMCs whereas
the double knockout mice had a higher collagen
content in their plaques.
There are no reports on MMP-1 knockout mice in
the literature. The predominant opinion was long
that no MMP-1 existed in the mouse, as only
MMP-13 was detected in mouse tissue. In 2001,
Balbin et al. succeeded in cloning two new MMPs
in the MMP gene cluster on mouse chromosome 9
and at least one of them, murine collagenase-like
A (Mcol-A) could represent the orthologue of
human MMP-146. Mcol-A and Mcol-B were
predominately present during mouse embryo-
genesis.
Transgenic mice expressing human MMP-1 in
macrophages on a apoE deficient background and
fed a Western diet for 16 weeks had earlier and
less extensive atheromatous lesions with less
collagen staining of the intima than apoE deficient
mice lacking the human MMP-1 gene47. No
difference was detected in SMC or macrophage
content. There was no evidence of plaque rupture
in the MMP-1 expressing mice.
MMP-3
MMP-3, also denoted stromelysin-1, is an MMP
showing activity against a wide range of substrates,
e.g. collagen types III, IV, IX and X, proteoglycans,
laminin, elastin and fibronectin. MMP-3 is also
involved in the activation of other MMPs (e.g.
proMMP-1, proMMP-8, proMMP-9 and
proMMP-13) as well as in autoactivation of pro-
MMP-348. Importantly, MMP-3 is not capable of
degrading the structurally essential type I collagen
fibres, which are highly responsible for the strength
of the fibrous cap8,9.
The effects of MMP-3 have been studied in
numerous clinical settings. Elevated serum and/or
plasma concentrations of MMP-3 have been
associated with a wide range of clinical conditions,
such as rheumatoid arthritis, systemic lupus
erythematosis49, rapidly destructive osteoarthritis
of the hip50, and different types of cancer, especially
in the metastatic phase51. Decreased plasma
concentrations of MMP-3, on the other hand, have
been found to be associated with agnogenic mye-
loid metaplasia, implicating that a lack of MMP-3
may play a role in fibrosis of the bone marrow52.
In the atherosclerotic vessel wall, MMP-3 is
expressed by vascular SMCs, macrophages and
endothelial cells. In addition, by immunoflour-
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escense technique, MMP-3 was found to be present
in ECM in areas of SMC proliferation in in-
flammatory bowel disease, both Crohn´s disease
and ulcerative colitis, but not in normal tissue from
the same patients53. This latter finding indicates that
MMP-3 enhances SMC migration and proli-
feration.
MMP-3 in atherosclerosis
Evidence of the presence of MMP-3 in athero-
sclerotic plaques was first reported by Henney et
al. in 199139, with use of in situ hybridisation
technique applied on atherosclerotic plaques ob-
tained from coronary arteries of heart transplant
recipients. The MMP-3 mRNA signal co-localized
both with SMCs and a subpopulation of macro-
phages containing visible intracellular lipid
deposits39. A few years later, Galis et al. reported
occurrence of MMP-3, along with MMP-1, MMP-
2 and MMP-9, in human atherosclerotic tissue,
specifically in SMCs and macrophage-derived
foam cells. In addition, areas rich in lymphocytes
also co-localized with MMP-3 and the other MMPs
tested38.
In a study by Schoenhagen et al. increased cell-
associated MMP-3 staining was associated with
positive arterial remodelling. The quantities of
inflammatory and interstitial cells were equal in
both positively and negatively remodelled vessels,
thus suggesting that MMP-3 expression is not
merely a consequence of increased inflammation54.
Measuring the MMP-3 concentration in the
circulation is a blunt but relatively easy way to
evaluate a possible influence of MMP-3 in diffe-
rent conditions. A drawback of most assays of
MMP-3 is that they are measuring both pro-MMP-
3, activated MMP-3 and MMP-3 bound to and
inhibited by TIMP. This makes it difficult to esti-
mate MMP-3 activity, not least the MMP-3 in the
vessel wall. In addition, very little is known about
the clearance of MMP-3 from the circulation.
Studies of MMP-3 concentration in serum or
plasma of patients with manifestations of CAD
have reached divergent results. In a study by Noji
et al., male patients with stable CAD had lower
plasma MMP-3 concentration than healthy
controls55 whereas Inoue et al. found the serum
MMP-3 concentration to be higher in coronary
sinus blood in patients with ACS than in patients
with stable CAD or in healthy control persons56,
even though there were no differences when
measuring the concentration in arterial blood. Also,
Yan et al. reported higher serum MMP-3 con-
centration in patients with ACS than in healthy
controls or patients with stable CAD57. Further-
more, Wu et al. demonstrated that the MMP-3 level
is higher in patients with stable angina pectoris than
in controls and also that higher levels of MMP-3
predicted a worse outcome in patients with CAD58.
In contrast, studies of both hyperlipidemic59 and
diabetic60 patients showed that affected individuals
had lower levels of MMP-3 than the corresponding
controls. In a study of hyperlipidemic but otherwise
healthy subjects, Beaudeux et al. found the serum
levels of MMP-3 to be higher in subjects with
carotid plaques than in subjects without signs of
carotid plaques as estimated by carotid ultrasound
examination61. Also, hyperlipidemic subjects
presented higher MMP-3 concentrations than
controls.
MMP-1
MMP-1, interstitial collagenase, is capable of
degrading intact type I collagen fibres, which are
otherwise resistant to most proteases, including
MMP-3. Collagen is the main extracellular com-
ponent of the fibrous cap of advanced athero-
sclerotic lesions. Most collagen is composed of type
I collagen fibres, about 70% of the total collagen
content8,62. The collagenases are required for the
initial degradation of the tightly winded collagen
triple helical structure. The resulting collagen
remnants are then accessible to further degradation
by other MMPs. Hence, MMP-1, along with
MMP-8 and MMP-13, is implicated in the degra-
dation of the fibrous cap.
MMP-1 in atherosclerosis
There is no evidence of MMP-1 expression in nor-
mal human arteries while it has been detected in
human atherosclerotic lesions38,41. Also, in a study
of carotid artery lesions, MMP-1 gene expression
was considerably increased in plaques with a thin
fibrous cap compared with plaques with a thick
fibrous cap63. MMP-1 present in the atherosclerotic
plaque is principally expressed by macrophages in
the shoulder region and the regions adjacent to the
lipid core, but also, to a lesser extent, by SMCs38,41.
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MMP-1 has been proposed, in conjunction with
MMP-13, to increase collagenolysis in human
atherosclerotic plaques40. Similarly, the inflamma-
tory cytokines IL-1β, TNF-α and IFN-γ , possibly
capable of inducing MMP expression, are expres-
sed in the atherosclerotic lesions, but undetectable
in normal arteries. In vitro experiments in THP-1
monocytes differentiated into macrophages showed
a 6.6-fold increase in the expression of MMP-1 on
differentiation, the increase being most pronounced
shortly after stimulation37.
There is limited information on circulating levels
of MMP-1 in the setting of stable CAD. No
difference in serum MMP-1 concentration was
detected between patients with hemodynamically
significant coronary stenosis and those without, in
an angiography study64. In a subgroup analysis of
the patients with significant CAD, those who had
at least one complex lesion had higher levels of
MMP-1 than those who had no complex lesion as
defined by angiographic criteria64. Also, two studies
on stable CAD have failed to detect any MMP-1
in circulating blood65,66. In a study of abdominal
aortic aneurysm (AAA), no difference in plasma
concentrations of MMP-1 was seen between
patients with AAA, patients with obliterative aortic
atherosclerosis and healthy controls67.
In a study by Inoue et al., the serum concentration
of MMP-1 in coronary sinus blood was higher in
patients suffering ACS than in patients with stable
angina pectoris or in healthy individuals undergoing
coronary angiography because of chest pain whose
angiograms were normal56. In contrast, Fukuda et
al. did not detect any difference in serum concentra-
tion of MMP-1 between patients with acute MI,
unstable angina pectoris or stable CAD, nor was
there any difference between patients with and
without signs of plaque rupture on investigation
with intracoronary ultrasound68.
Six studies have investigated MMP-1 levels at dif-
ferent time points during the acute stage of MI and
the first month of recovery69-74. The earliest one,
presented in 1997, had no control group included,
but could detect an increase in serum concentration
of MMP-1 at one and two weeks after the index
event69. The remaining five studies included a
control group of either healthy individuals70,72,74 or
patients with CAD but without signs of acute
MI71,73. There was no significant difference in the
levels of MMP-1 between MI patients and controls
at any time point investigated in two of these
studies70,74. In two other studies, the levels of MMP-
1 were higher in the MI group already at admission,
as compared with the control group71,72, and in one
of these, the levels increased significantly at one
and two weeks after the MI71. On the other hand,
Eckart et al. did not detect any difference in serum
MMP-1 level at admission between patients with
and without MI, but there was a significant increase
in MMP-1 levels in MI patients 24 hours later73.
Of note, only one study demonstrated elevated
levels in patients at one month after the index MI
as compared with controls71. Overall, these studies
show fluctuating MMP-1 levels in the course of
MI, as levels increase either early (1-2 weeks) or
very early (24 hours) after the onset of MI, and
then diminish early as they have returned to baseline
at one month. Accordingly, MMP-1 might be
involved in the acute inflammatory process of MI.
Genetic regulation of MMP
expression
Deoxyribonucleic acid (DNA) with the four nu-
cleotides adenine (A), cytosine (C), guanine (G),
and thymine (T) is the foundation of all living
creatures and plants, essentially storing the com-
plete information needed for all biological pro-
cesses such as embryogenesis, development and
daily life. The sequence of nucleotides decides the
amino acid sequence of the proteins and thereby
their structure and function
A defined sequence of DNA constitutes a gene.
There are approximately 32.000 genes in the human
genome42,75. Most genes include a promoter region
and a transcription unit with exons and introns.
Protein synthesis starts with the transcription of
DNA into mRNA, a molecule transferring the
genetic information from DNA to protein synthesis.
The transcription starts with formation of the
transcription complex, including RNA polymerase
II and several transcription factors attaching to the
promoter region of the gene. The nucleotide
sequence of the promoter region of the gene
influences the binding properties of transcription
factors. Transcription factors are nuclear proteins
acting as either activators or repressors of the
transcriptional activity, in this way modulating
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protein synthesis. During splicing, mRNA is modi-
fied as the introns are deleted and then translated
into an amino acid sequence, where a nucleotide
triplet corresponds to one amino acid. Eventually
the amino acid sequence folds into the protein
structure intended.
DNA polymorphisms are naturally occurring
variations in the nucleotide sequence that may
influence the phenotype. Four types of polymor-
phisms are identified: i) single nucleotide poly-
morphisms (SNPs), ”misspellings” where a single
nucleotide has been switched, e.g. G instead of A,
ii) insertion of a nucleotide, e.g. 6A instead of 5A,
iii) deletion of a nucleotide, i.e. one nucleotide is
missing, and iv) microsatellite repeats, short
nucleotide sequences that are repeated a significant
number of times. There are currently more than 10
million SNPs listed in the National Institutes of
Health (NIH) database of SNPs (http://
www.ncbi.nlm.nih.gov/projects/SNP/snp_
summary.cgi), including insertion/deletion and
small microsatellite repeats. These polymorphisms
may, depending on their location, influence
expression of the gene or function of the protein
product. Examples on polymorphisms influencing
transcription, splicing and mRNA stability have
been described.
Haplotype, or more specifically ”haploid geno-
type”, is a specific combination of alleles within
one single gene or in related genes on the same
chromosome. Alleles included could be more or
less linked to each other. Single polymorphisms of
a gene may not influence the phenotype but when
combining into haplotypes they might. The closer
two alleles are situated on the chromosome, the
more linked they are, and the more likely they will
be passed on to the next generation together. Thus,
the haplotype reflects the linkage disequilibrium
(LD), which can be estimated by calculating the
so-called LD coefficient. The genes coding for
several MMPs (MMP-1, MMP-3, MMP-7, MMP-
8, MMP-10, MMP-12, MMP-13, MMP-20 and
MMP-27) are located in a cluster in the same re-
gion on chromosome 11 implicating that the alle-
les of these MMPs may be in strong LD33 (www.
ensemble.org).
Atherosclerosis and CAD are multifactorial dis-
eases. The set of alleles of the individual interacts
with environmental modifying factors to influence
the risk of the individual to attract CAD. The
association of a genotype with the studied disease
outcome, i.e. MI or CAD, is virtually a statistical
phenomenon that hardly translates into predicting
the risk of a single individual as the predisposing
genetic risk is greatly modified by environmental
agents that change over time and interact to
influence genetic susceptibility. Association studies
can be performed either with a genome-wide
screening approach, which is unbiased in relation
to assumptions on particular genes, or with a
candidate gene approach. The latter approach
addresses an a priori appointed gene, which could
be of interest e.g. from functional studies. Hundreds
of genes, each with various variants, have been
suggested to influence the risk of MI and CAD in
association studies76 but the newly presented
INTERHEART study of 15.152 MI patients and
14.820 controls investigated in 52 countries re-
vealed nine, mainly environmental, risk factors
accounting for 90% of the risk in men and 94% of
the risk in women to suffer MI77. This study
reinforces the notion that atherosclerosis and its
clinical manifestations are very complex conditions
where we will not find single gene polymorphisms
to have more than quite minor effects.
MMP-3 -1612 5A/6A – a functional
polymorphism
The gene coding for MMP-3 is located on the long
arm of chromosome 11 in the region 11q22.2-
22.378. In 1995, Ye et al. identified a common poly-
morphism in the promoter region of the MMP-3
gene, located 1612 base pairs upstream of the
transcription start site. This polymorphism is an
insertion/deletion polymorphism with one allele
containing a run of five adenosines (5A), and the
other allele containing a run of six adenosines
(6A)79. The earlier designation of this poly-
morphism, which still appears in the literature, has
been -1171 5A/6A as it was initially sequenced
from a clone with an inversion. Beyzade et al.
identified an additional six SNPs in the MMP-3
gene in 2003, but the effect of MMP-3 gene
variation was mainly attributable to the -1612
5A/6A promoter polymorphism80.
Transient transfection experiments in cultured
fibroblasts and vascular SMCs have indicated a
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functional role of the polymorphism since the 5A-
allele expressed a two-fold higher activity of the
reporter gene than did the 6A-allele48. The allele-
specific expression is probably caused by a re-
pressor nuclear protein binding preferentially to the
6A-allele and resulting in lower expression of
MMP-3. This hypothesis has been supported by
the finding that the MMP-3 gene expression in skin
biopsies of healthy men was significantly lower in
individuals homozygous for the 6A-allele com-
pared with those homozygous for the 5A-allele, as
was MMP-3 protein expression81.
The allele frequency of the MMP-3 -1612 5A/6A
polymorphism appears to be quite different in a
Caucasian compared with an Asian or Afro-Ame-
rican population. Whereas the 5A-allele frequency
in the Caucasian population is about 50%, it is less
than 15% in an Asian or Afro-American popula-
tion82.
MMP-3 -1612 5A/6A polymorphism and
circulating MMP-3
The first study to show a clear association of
circulating levels of MMP-3 to the MMP-3 -1612
5A/6A promoter polymorphism was the one of
Mattey et al., exploring 197 patients with the
diagnosis of rheumatoid arthritis. Among these
patients the serum MMP-3 concentration was
strongly associated with the 5A/6A polymorphism
as the serum concentration increased with the
number of 6A-alleles83. The same result has later
been reached in an Australian cohort of CAD
patients, as reported in an abstract presented by
White et al. at the American Heart Association
Scientific Sessions of 200584. The findings of
increasing levels of MMP-3 with a rising number
of 6A-alleles are intriguing, as earlier in vitro
studies have reported the 5A-allele to increase the
expression of MMP-348.
Two smaller studies, both exploring carotid intima-
media thickening (IMT), have failed to observe any
relationship of circulating levels of MMP-3 to the
5A/6A genotype85,86. In yet another study, 103
patients with rheumatoid arthritis the serum MMP-
3 concentration did not differ between the geno-
types87.
MMP-3 -1612 5A/6A polymorphism and
risk of CAD
The MMP-3 gene harbouring the -1612 5A/6A
promoter polymorphism was early recognized as
a candidate gene for several conditions, including
atherosclerosis. Several reports are found in the
literature on the association of the MMP-3 -1612
5A/6A polymorphism and the risk of MI and
severity of CAD. Regrettable, these studies have
reached divergent results (Table 2 and 3) and it is
difficult to arrive at a comprehensive conclusion
as they have been performed in various populations,
differ in gender mix and have studied different
outcomes of CAD. When it comes to extension
and severity of CAD, as measured by coronary
angiography, most of the studies have shown the
6A-allele to be associated with occurrence or more
severe disease80,84,88,89 as well as with faster CAD
progression79,90-92 (Table 2). However, one of them,
notably the largest one, failed to detect any
genotype-specific differences93. Only one study
indicated the 5A-allele to confer higher risk of
angiografically proven CAD94. In addition, in an
autopsy study, Pöllänen et al. found the 5A-allele
to be associated with larger calcified lesions in the
coronary artery trees of male sudden death victims,
53-69 years old, in Finland95 (Table 4).
In the association studies of risk of MI, summarized
in Table 3, the majority of the studies show the
5A-allele to be associated with higher risk80,96-99
whereas one study points to the 6A-allele as being
harmful100. In addition, two studies failed to prove
association with either allele88,95.
Four studies have explored a divergent mix of CAD
outcomes (Table 4). Two of them studied the risk
in healthy individuals101,102 and the other two studied
the risk of a recurrent event in patients who already
had suffered a manifestation of CAD91,103. In the
study by Humphries et al.101, healthy men carrying
the 6A-allele had a higher risk of an event (MI,
CABG or death) than 5A-allele carriers. In contrast,
Ye et al. could not demonstrate any association of
the polymorphism with the combined endpoint of
MI, angina pectoris, CABG or PCI102. In the two
studies of prognosis after a CAD event, the first
one confirmed the 6A-allele to be harmful as
patients carrying the 6A-allele had twice as many
events (MI, CAD death, symptom driven inter-
vention, stroke or transient ischemic attack (TIA)
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Reference n, total Population % male, total 6A-allele freq, Higher risk
or P/C or P/C total or P/C allele
Schwarz et al.88 1848 Caucasian 100 0.49/0.51 6A
Hirashiki et al.89 1011/650 Asian 69/56 N.A. 6A
Beyzade et al.80 1070 Caucasian 67 0.49 6A
White et al.84 44* Caucasian N.A. N.A. 6A
Ye et al.79 72 Caucasian 100 0.51 6A
Humphries et al.90 187** Caucasian 100 0.60 6A
deMaat et al.91 249** Caucasian 100 0.49 6A
Humphries et al.92 287 *** Caucasian 85 0.52 6A
Hoppman et al.93 2667 Caucasian 75 0.51 No difference
Kim et al.94 131/117 Asian 68/50 0.76/0.85 5A
Paper I 243 Caucasian 82 0.53 No difference
and death of all causes) as patients homozygous
for the 5A-allele during 2 years of follow-up91. This
study, including patients with stable angina and at
least one significant coronary stenosis was a
secondary preventive, placebo-controlled study of
pravastatin, a lipid-lowering drug. Association
between the 6A-allele and events was only present
in the placebo group. The second study reported
on 5A/6A polymorphism in relation to prognosis
after a first MI. The 5A/6A polymorphism was
recognized as an independent predictor of a new
event (recurrent angina, non-fatal MI or cardiac
death) as the frequency of the 5A-allele was higher
in the event group, resulting in an adjusted hazard
ratio of 2.51 for patients carrying the 5A-allele103.
Table 2. Association studies of MMP-3 -1612 5A/6A promoter polymorphism on risk/severity/progression of
angiographic coronary artery disease
P/C Patients/Controls; *plaque area as estimated by intravascular ultrasound (IVUS); **placebo treated group only; ***balloon
treated group only; N.A., not available
Reference n, total Population % male, total 6A-allele freq, Higher risk
or P/C or P/C total or P/C allele
Terashima et al.96 330/330 Asian 82/78 0.70/0.82 5A
Beyzade et al.80 132/780 Caucasian 67 0.43/0.50 5A
Nojiri et al.97 466/335 Asian 86/63 0.82/0.88 5A
Liu et al.98 150/150 Asian 84 0.65/0.80 5A
Zhou et al.99 509/518 Asian 82/78 0.81/0.86 5A
Yamada et al.100 2374/1778 Asian 75/60 0.85/0.79 6A
Schwarz et al.88 1848/515 Caucasian 100 0.49/0.51 No difference
Pöllanen et al.95 86/204 Caucasian 100 0.59 No difference
Paper I 374/385 Caucasian 82 0.53/0.49 No difference
Table 3: Association studies of MMP-3 -1612 5A/6A promoter polymorphism and risk of myocardial infarction
P/C Patients/Controls
Summarizing all studies concerning the association
of the MMP-3 -1612 5A/6A promoter poly-
morphism with different manifestations of CAD,
there is a discernible pattern of the 6A-allele
promoting atherosclerosis progression in a stable
manner whereas the 5A-allele seems to increase
the risk of acute complications of atherosclerosis
like MI, thus implicating a higher risk of developing
vulnerable plaques. This line of reasoning is
supported by studies of atherosclerosis in other
arterial localizations (Table 4). Two studies on
carotid IMT85,104 and one of carotid stenosis105 found
the 6A-allele to be associated with more advanced
lesions, while the 5A-allele has been associated
with ischemic stroke, the acute complication of
atherosclerosis of the carotid artery106. In contrast,
the largest study in this field, comprising 1109
healthy individuals, could not detect any association
of the 5A/6A polymorphism with carotid IMT107.
In yet another study, both the 5A/5A and the
6A/6A genotypes had greater carotid IMT than
heterozygotes86. Finally, a study of aortic stiffening
in healthy subjects older than 60 years also showed
both homozygous groups to have higher large artery
stiffness than the heterozygous group81.
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In recent years new forms of genetic association
studies have emerged. To refine the case-control
approach, affected individuals are collected together
with unaffected siblings and/or parents. In one study
of family-based association, the combined trans-
mission disequilibrium test (TDT)/sib-TDT and the
pedigree disequilibrium test (PDT), failed to con-
firm any association of the 5A/6A polymorphism
with CAD, as defined by a history of acute MI,
unstable angina or significant CAD at angio-
graphy108 (Table 4). In the latter study, the outcome
tested combined the acute MI and the stable CAD
phenotypes, which may have masked associations
with the different phenotypes going in opposite
directions. In addition, the number of studied
families was quite small even though the post-hoc
power calculations done by the authors stated that
the study had >80% power to detect a deviation of
allele transmission from 50% to 60% using the
combined sibTDT/TDT.
MMP-1 polymorphisms
The gene coding for MMP-1 is located in the q21-
22.1 region of chromosome 1178. One common
polymorphism in the promoter region was identified
already in 1998, the MMP-1 -1607 G/GG promoter
polymorphism, and it has subsequently been exten-
sively investigated in various diseases, predo-
minantly different malignancies109-111. In an experi-
mental study in fibroblasts and melanoma cells, the
GG allele was found to be associated with higher
transcriptional activity109. This MMP-1 promoter
polymorphism has also been studied in relation to
atherosclerosis by Ye et al., who reported lower risk
of CAD in GG homozygotes than in G homo-
zygotes102. In contrast, no association was found
with the risk of MI in a larger study by Nojiri et
al.97. In addition, no association was found between
-1607 G/GG genotype and atherosclerotic lesion
development in the abdominal aorta of young men
in an autopsy study conducted by Nordskog et al.112,
nor was the MMP-1 -1607 G/GG promoter
polymorphism found to be associated with carotid
stenosis105.
The MMP-1 -422 T/A, -340 T/C and -320 T/C pro-
moter polymorphisms were identified by Thiry-
Blaise et al. in 1995 in a study of osteoporosis, but
did not influence the risk of disease when analysed
individually113, and no haplotype analysis was per-
formed.
Jurajda et al. reported the presence of the MMP-1
-519 A/G promoter polymorphism in 2002, but no
report is available suggesting that this poly-
morphism is associated with any disease114. Also,
this polymorphism was closely linked to the afore-
mentioned, as the A
-519
 allele more often occurs with
the GG
-1607
allele, and the G
-519
 allele more often
occurs with the G
-1607
 allele114.
Gender aspects of CAD
The incidence of MI in Sweden in the last ten years
has been about four-fold higher among men than
women younger than 60. At ages over 80, the
incidence is similar. Conversely, in the age group
below 60 years, the one-year mortality rate is higher
among women (5%) than men (4%)29. Thus, women
contract symptomatic CAD less frequently at
younger age, but when they do, their prognosis is
more dismal. As women become post-menopausal,
the risk of CAD and MI gradually increases, and it
has been proposed that oestrogen would exert a
protecting effect115-117. However, hormone replace-
ment therapy (HRT) with a combination of oestro-
gen and progestin has not proven to protect post-
menopausal women from CVD, neither as a
secondary preventive strategy as was tested in the
Heart and Estrogen/progestin Replacement Study
(HERS)118, nor as primary prevention as illustrated
by the early interruption of the oestrogen and pro-
gesterone treatment arm of the Women’s Health
Initiative (WHI) study119. In both these studies HRT
tended to increase the CAD event rate. In a review
published by the Cochrane Collaboration in 2005,
one of the conclusions is that HRT is inappropriate
for the prevention of chronic disease, including
CAD120.
In the past five years, 3850 patients (35% women)
underwent coronary angiography at Danderyd
Hospital according to the Swedish Coronary Angio-
graphy and Angioplasty Registry (SCAAR). The
proportion of women having no significant lesion
(>50% diameter stenosis) was 45% whereas the
corresponding figure was 20% for men. This is con-
sistent with less extensive CAD in women found
in several other registry and interventional studies
where gender differences have been explored121-126.
Histological studies of coronary thrombosis in
sudden death victims have revealed a higher fre-
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quency of thrombus overlying a superficial erosion
instead of plaque rupture in women than in men127.
In addition, in the eroded plaques the infiltration of
macrophages and T-cells was less pronounced, and
clusters of SMCs more common than in the ruptured
plaques, indicating a lower inflammatory activity.
The plaque rupture etiology has been shown to be
more frequent in women over 50 years of age than
in women below 50 years128. Also, women more
frequently have stable angina than MI as their first
manifestation of CAD when compared with men115.
Gender difference in MMPs
Plasma levels of MMP-3 were significantly lower
in women as compared to men in normal subjects,
and similar non-significant trends were seen in
patients with RA, osteoarthritis, systemic lupus
erythematosus and scleroderma49. On the other
hand, no association of serum concentrations of
MMP-3 or MMP-9 with gender was found in a
study of hyperlipidemic subjects61. Circulating
plasma concentrations of MMP-2 and MMP-9 did
Little is known about possible sex hormone effects
on MMPs. 17β-oestradiol decreased the expression
of MMP-1 but had no effect on MMP-3 or MMP-
13 expression in osteoarthritic chondrocytes130. A
recent study of human aortic SMCs showed that
testosterone increased MMP-3 protein two-fold
compared with control cells and cells cultured with
both oestrogen and progesterone131. The increase
was mainly due to increased MMP-3 transcription.
In contrast, MMP-2 gene and protein expression
were unchanged despite the influence of sex
steroids. Furthermore, the collagen deposition was
reduced and elastin deposition increased in the
presence of oestrogen and progesterone in com-
bination, resulting in a highly increased elastin/
collagen ratio131. Macrophage infiltration and
MMP-9 expression were decreased by oestradiol
in a rat model of AAA132.
not show any gender-specific difference in a study
of healthy subjects129 whereas plasma MMP-9
concentration turned out to be higher in women than
men amongst patients with stable CAD124.
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HYPOTHESIS AND AIMS
Inflammatory and genetic mechanisms influence the synthesis and degradation of arterial vessel wall
matrix through the effects of matrix metalloproteinases, and have a prominent role in initiation, progres-
sion and rupture of atherosclerotic plaques.
Hypothesis
Aims
 to study the effect of the MMP-3 -1612 5A/6A promoter polymorphism on circulating levels of
MMP-3 and angiographically assessed CAD
 to explore the serum MMP-3 concentration in relation to the acute stage of MI
 to identify functional polymorphisms of the MMP-1 gene that might influence the expression and
plasma MMP-1 concentration, and the risk of MI
 to study circulating levels of inflammatory cytokines in postinfarction patients, and their relations
to the levels of MMP-3 and MMP-1
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SUBJECTS  AND METHODS
Study populations
The present thesis is based on three different study
populations, two of which were collected by our
group in Stockholm (paper I, II, III and IV) and the
third explored in collaboration with our co-work-
ers in Southampton (paper III).
SCARF (papers I, III and IV)
The Stockholm Coronary Artery Risk Factor
(SCARF) study was designed for studies of genetic,
biochemical and environmental risk factors pre-
disposing to MI. During the period of January 1996
to December 2000, all patients less than 60 years
of age, who were admitted for acute MI to the
coronary care units of the three hospitals in the
northern part of Stockholm (Danderyd Hospital,
Karolinska Hospital and Norrtälje Hospital) were
screened for inclusion in the SCARF study (Figure
1). A total of 755 patients were considered, of whom
433 patients entered the study. Of the remaining
322 patients, 179 met one or more predefined
exclusion criteria (previous MI (n=102), type 1
diabetes mellitus  (n=23), renal insufficiency
defined as serum creatinine >200 μmol/L (n=9),
any chronic inflammatory disease (n=13), drug
addiction (n=10), psychiatric disease (n=3) or un-
willingness to enrol in the study (n=19)) and 143
patients were not included for logistic and psycho-
social reasons, resulting in a participation rate of
eligible patients of 76%.
Figure 1: Patients screened for the SCARF study.
Numbers and reasons for exclusion.
Figure 2: Patients not completing the SCARF study
protocol. Numbers and reasons for drop-out.
Of the 433 patients entering the study (Figure 2),
46 patients did not complete the programme; 19
withdraw their consent, 19 were excluded due to
occurrence of concomitant disease (n=12) or pro-
tocol violation (n=7), five patients failed to com-
plete the programme and three died. Thus, 387
patients completed the programme and for each
patient included, a sex- and age-matched healthy
control person was recruited from the general po-
pulation of the same county.
755 patients were screened
102 previous MI
23 type 1 diabetes
9 renal insufficiency
13 inflammatory disease
10 drug addiction
3 psychiatric disease
19 unwillingness
143 logistics and other
433 patients entered the study
hemical and environmental risk factors
predi posing to MI. During the period of January
1996 to December 2000, all patients less than 60
years of age, ho were admitted for acute MI to
the coronary care units of the thr e hospitals in 
  ì
433 patients
19 withdrawal
414
12 concomitant disease
402
7 protocol violation
395
5 unknown
3 deaths
390
387 patients
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Three months after the index cardiac event, patients
and control subjects were interviewed about back-
ground facts, such as ethnicity, social situation,
lifestyle characteristics, medical history and medi-
cation, and a medical examination was performed.
Blood samples were drawn on the same occasion
under fasting conditions. Basic characteristics and
biochemical analyses are summarized in Table 5.
All patients included at the Danderyd and Norr-
tälje hospitals (n=269) were offered coronary
angiography, of whom 243 accepted to be included
in the coronary angiography substudy. Coronary
angiography was performed, if needed for clinical
reasons, during the initial hospital stay (n=35), or
otherwise three months later (n=208).
The study was approved by the Ethics Committee
of the Karolinska University Hospital, and
conducted in agreement with the Declaration of
Helsinki. All subjects gave their informed consent
to participation.
Patients (n=387) Controls (n=387) p-value
Age 54 (49-57) 54 (49-57)
Male (%) 82 82
Smokers (%) 50 25 < 0.0001
Family history of CHD (%) 42 21 < 0.0001
Diabetes (%) 11 0 < 0.0001
Hypertension (%) 34 6 < 0.0001
Hyperlipidemia (%) 70 16 < 0.0001
BMI (kg/m2) 26.8 (24.7-29.7) 25.6 (23.8-27.8) < 0.0001
SBP (mmHg) 130 (118-140) 128 (118-140) ns
DBP (mmHg) 80 (75-88) 80 (78-88) ns
Glucose (mmol/L) 5.3 (5.0-5.9) 4.8 (4.6-5.2) < 0.0001
Plasma cholesterol (mmol/L) 5.0 (4.3-5.7) 5.4 (4.7-6.1) < 0.0001
Plasma triglycerides (mmol/L) 1.6 (1.2-2.2) 1.2 (0.8-1.6) < 0.0001
LDL-cholesterol (mmol/L) 3.2 (2.5-3.9) 3.4 (2.9-4.2) < 0.0001
HDL-cholesterol (mmol/L) 1.1 (0.9-1.3) 1.4 (1.1-1.6) < 0.0001
Insulin (pmol/L) 47.0 (32.0-69.0) 36.0 (27.5-50.5) < 0.0001
Proinsulin (pmol/L) 5.1 (3.4-7.5) 3.5 (2.6-5.4) < 0.0001
CRP (mg/L) 1.5 (0.7-3.4) 1.0 (0.5-1.8) < 0.0001
Cystatin C (mg/L) 0.81 (0.73-0.93) 0.83 (0.77-0.90) ns
Fibrinogen (g/L) 3.8 (3.3-4.4) 3.5 (3.1-4.0) < 0.0001
PAI-1 (IU/mL) 12.6 (4.8-22.8) 7.5 (3.0-17.6) < 0.0001
Table 5: Basic characteristics of patients and control subjects in SCARF
Values are median (interquartile range) or percentage. CHD, coronary heart disease; BMI, body mass index; SBP, systolic
blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive
protein; PAI-1, plasminogen activator inhibitor-1.
TREOC (paper II)
During the time period of 1991 through 1995, 222
consecutive patients admitted to the coronary care
unit at the Danderyd hospital with STEMI treated
with thrombolysis were enrolled in the Throm-
bolysis and REOCclusion (TREOC) study, a
longitudinal cohort study with a two year follow-
up133. Three hundred and eighty patients were
eligible for the study thus resulting in a participation
rate of 58%. Reasons for patients not entering the
study were mainly logistic, but also cardiogenic
shock, unwillingness and alcohol abuse. However,
for a minor part (22 patients) the reason could not
be identified. All patients were below 75 years of
age and 76% were men. Time elapsed since the
onset of symptoms was less than 12 hours and
diagnosis of STEMI was made by conventional
electrocardiographic findings. The majority of the
patients (89,3%) received streptokinase as
thrombolytic therapy and the remaining patients
were given front-loaded recombinant tissue-type
plasminogen activator.
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Blood samples were drawn at admission (within
12 hours of onset of symptoms) and 48 hours, 6
days and 3, 6, 12 and 24 months after the admission.
Coronary angiography was performed before
discharge and at 6 months after the acute event.
Patients were excluded from further blood samp-
ling if they had a second MI or if they were
subjected to PCI or CABG during follow-up. A
total of 14 patients died in the course of follow-up
whereas 109 patients completed the two-year
program. One hundred and sixty-four patients were
event-free survivors and had blood samples stored
for DNA sequencing and for serum analyses from
all investigations up to the three months control
and formed the basis for the study included in this
thesis. Two hundred and five patients had DNA
isolated at inclusion, whereas 41 were either
excluded due to events (n=35) or lost to follow-up
(n=6). Basic characteristics of patients, both those
included and excluded in this study, are presented
in Table 6.
All patients gave informed consent to participation
and the Ethics Committee of the Karolinska
University Hospital approved the study.
SAS, the British cohort (paper III)
The Southampton Atherosclerosis Study (SAS)
conducted at the Wessex Cardiothoracic Unit,
Southampton General Hospital, included 1501
consecutive patients undergoing diagnostic or
interventional coronary angiography134. All patients
with significant CAD, defined as at least one
coronary artery diameter stenosis of >50%, were
included in this study. The participants were divided
into two groups by history of MI; 639 patients had
suffered an MI, and 538 had not, constituting the
MI and non-MI groups respectively. Clinical and
demographic data were recorded and serum lipids
measured. MI was diagnosed according to stan-
dard clinical criteria including electrocardiographic
and/or enzymatic changes. Characteristics of MI
and non-MI groups are given in Table 7.
The study was approved by the South and West
Local Research Ethics Committee, and all subjects
gave written consent.
Included (n=164) Excluded (n=41)
Age (years) 60 (10) 64 (9)*
Males 125 (76) 35 (85)
Current smokers 75 (46) 10 (24)*
Family history of CHD 103 (63) 20 (49)
Previous MI 20 (12) 12 (30)*
Diabetes 18 (11) 3 (7)
Hypertension 52 (32) 10 (24)
SBP (mmHg) 152 (26) 149 (30)
DBP (mmHg) 92 (15) 88 (14)
BMI (kg/m2) 25.9 (3.7) 24.5 (3.1)*
Plasma cholesterol (mmol/L) 5.8 (0.9) 5.8 (0.9)
LDL cholesterol (mmol/L) 4.0 (0.9) 4.1 (0.9)
HDL cholesterol (mmol/L) 1.1 (0.3) 1.0 (0.2)
Plasma triglycerides (mmol/L)† 1.5 (1.1-2.2) 1.7 (1.2-2.5)
Table 6: Basic characteristics of patients at baseline in TREOC
Values are mean (+/-SD) or number of patients in group (%), †for skewed data
median (interquartile range), * p<0.05 by student t-test or chi-square, CHD,
coronary heart disease; MI, myocardial infarction; SBP, systolic blood pressure;
DBP, diastolic blood pressure; BMI, body mass index; HDL, high density lipoprotein
26 Ann Samnegård
MI group Non-MI group p-value
(n=639) (n=538)
Age (years) 62.9 (10.0) 63.8 (9.9) ns
Gender (male, %) 79 73 <0.05
Body mass index (kg/m2) 27.6 (4.3) 27.5 (4.1) ns
Smokers (current and previous, %) 77 71 <0.05
Statin treatment (%) 60 52 <0.01
Plasma cholesterol (mmol/L) 5.0 (1.0) 5.3 (1.1) <0.01
HDL cholesterol (mmol/L) 1.2 (0.3) 1.3 (0.3) <0.05
Plasma triglyceride (mmol/L) 1.8 (1.2) 1.9 (1.1) ns
Hypertension (%) 42 49 <0.05
Type 2 diabetes (%) 10 10 ns
Table 7. Basic characteristics of  SAS
Mean (standard deviation) are shown for quantitative variables. HDL, high-density lipoprotein
Biochemical analyses
Fasting plasma concentrations of cholesterol and
triglycerides and concentrations of cholesterol and
triglycerides in very low density lipoprotein
(VLDL), LDL and high density lipoprotein (HDL)
were determined by a combination of preparative
ultracentrifugation, precipitation of apo-B contain-
ing lipoproteins and lipid analyses135.
Commercially available kits were used for analy-
sis of insulin and proinsulin (ELISAs from DAKO
Ltd, Cambridgeshire, UK), fibrinogen (clotting
assay IL-Test Fibrinogen-C from Instrumentation
Laboratory Co., Milan, Italy), and plasminogen
activator inhibitor-1 (PAI-1) activity (Cromolize
PAI-1 from Biopool International, Umeå, Sweden).
High sensitivity CRP (hsCRP; N high sensitivity
CRP) and cystatin C (N latex Cystatin C) were
measured by particle-enhanced immunone-
phelometry with specific assays in the BN system
(Dade Behring, Liederbach, Germany).
MMP quantification
MMP levels were measured using sandwich
enzyme-linked immunosorbent assays (ELISA).
ELISA is a robust and commonly used technique
for quantification of proteins in body liquids and
in cell culture supernatants. Briefly, there is a solid
phase antibody to the MMP being measured, the
study sample is added and the MMP attaches to
the antibodies. After washing away the unbound
material, a second MMP-antibody labelled with
an enzyme (peroxidase) is added which binds to
the MMP caught in the solid phase. After a second
washing, a peroxidase substrate (tetramethyl-
benzidine) is added that generates a coloured
product, the amount of which is proportional to
the amount of MMP present in the study sample.
The intensity of the colour is quantified by a
spectrophotometric reading at 450 nm. A possible
drawback, depending on the antibody, in the MMP
setting is that it does not discriminate the different
forms of MMP present in the circulation (pro-
MMP, active MMP and MMP bound to TIMPs)
resulting in quantification of total MMP.
MMP-3 was quantified in serum samples with an
immunoassay from R&D Systems (Abingdon,
UK). The MMP-3 inter-assay coefficient of
variation (CV) for a control sample was 8.9%. The
lower detection level is 0.009 ng/mL according to
the manufacturer.
MMP-1 was quantified in plasma samples with an
ELISA from GE Healthcare (Uppsala, Sweden)
The MMP-1 inter-assay CV for a normal citrate
plasma was 8%, and the intra-assay CV was always
lower than 2%. Sensitivity level of measurement
is 1.7 ng/mL according to the manufacturer.
Cytokines
Plasma concentrations of IL-1α, IL-1β, IL-2, IL-
4, IL-6, IL-8, IL-10, IFN-γ , TNF-α and MCP-1
were measured using a biochip array system based
on standard sandwich and competitive immuno-
assay techniques (evidence®, Randox Laboratories
Ltd., Co Antrim, UK)136.
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Genotyping
Genotyping can be performed using a variety of
methods, all of which are based on four general
mechanisms, which are: allele-specific hybridisa-
tion, nucleotide incorporation, oligonucleotide liga-
tion and invasive cleavage137. In this thesis the
allele-specific nucleotide incorporation principle
has been utilized in the pyrosequencing method.
In addition, restriction fragment length poly-
morphism (RFLP) analysis, the classical geno-
typing method, was used in paper III.
Pyrosequencing (papers I and II)
Pyrosequencing is a sequencing technique deve-
loped in Sweden and first described by Nyrén138-
140. This technique is a suitable method to detect
SNPs and insertion/deletion polymorphisms as the
sequencing of the DNA is done at the polymorphic
site. The nucleotides are added one at a time in a
pre-specified order, exclusive for the SNP studied,
and they are incorporated into the extending DNA-
primer if suitable. On incorporation a pyrophos-
phate is released which by a luciferase produces a
light signal that is detected and presented as a peak
in the pyrogram (Figure 3). The height of the peak
is proportional to the amount of incorporated
nucleotide. This method was used in genotyping
for the MMP-3 -1612 5A/6A promoter polymor-
phism in papers I and II.
DNA was prepared from peripheral blood cells
using a genomic DNA isolation kit (Qiagen Inc,
Valentia, CA) and stored frozen in 96-well arrays.
For determination of  -1612 5A/6A MMP-3 geno-
type, DNA was amplified by a nested polymerase
chain reaction (PCR) to get a clean PCR product
for the pyrosequencing analyses. The primers used
in the outer PCR were forward primer 5’-
CTCCACTGTTTCTTCCTGGAATTC-3’ and
reverse primer 5’-CAAGTGATTCTCCTGCCT
CAACCT-3’. The inner PCR used the forward
primer 5’-CTCTGTTCTCCTTGTCCTCATATC-
3’ and the biotinylated reverse primer 5’-GGCAC
CTGGCCTAAAGACATTTTA-3’.
The nucleotide sequence was then identified by
pyrosequencingTM using the PSQTM 96 System with
PSQTM 96 SNP Reagent Kit in paper I, and the
PSQTM 96 MA System with PSQTM 96 MA Pyro
Gold Reagents in paper II (Pyrosequencing AB,
Uppsala, Sweden). The primer used for pyro-
sequencing was 5’-AATCAGGACAAGACATG
GTTTTT-3’. The dispensation order of the nucleo-
tides was ACTACATCA. The resulting pyrograms
of the MMP-3 -1612 5A/6A promoter poly-
morphism are presented in Figure 3.
5A/5A
5A/6A
6A/6A
CTTTGATGGGGGG(A)AAAAACCATGTCTT
TTTTTGGTACAGAA
MMP-3 -1612 5A/6A promoter polymorphism Figure 3: The PyrogramTM, an
illustration of pyrosequencing
results for each genotype of the
MMP-3 –1612 5A/6A promoter
polymorphism. The added nucleotide
sequence is on the X-axis. The signal
peak reflects the number of incor-
porated nucleotides in the complemen-
tary DNA strand for the different
genotypes. The dispensation order of
the nucleotides has been designed to
create an allele-specific out-of-phase
shift of the sequencing. When adding
the first C, it is incorporated only in
the 5A-allele, giving the intense signal
from the 5A-allele, as the 6A-allele
requires an additional T before any C
can be incorporated.
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RFLP analysis (paper III)
Analysing RFLP is the prototypic genotyping
method for SNPs. After amplification of the DNA
region of interest by PCR, a restriction enzyme (or
restriction nuclease) is added which specifically
recognizes one of the two allele variants of the SNP
and splices the DNA on recognition. The product
is then separated by gel electrophoresis and
visualized by fluorescent staining. Heterozygous
samples appear as two bands whereas homozygous
samples present either of the two bands.
For each of the seven identified MMP-1 promoter
polymorphisms, a DNA sequence containing the
polymorphic site was amplified by PCR using
predefined primers. The amplicons were digested
with an appropriate restriction endonuclease for
each SNP; those were Xmn I (for -1607 G/GG),
Hind III (for -839 G/A), Msp I (for -755 G/T), Kpn
I (for -519 A/G), Ban I (for -422 T/A), Afl II (for
-340 T/C), and Hae III (for -320 T/C), respectively.
Digests were subjected to gel electrophoresis, and
DNA was detected by post staining of the gel with
Vistra Green in the SAS patients and ethidium-
bromide in the SCARF cohort, and visualized using
a fluoroimager to determine genotypes.
Genotyping for all seven polymorphisms in the
SAS patients was performed at the Human
Genetics Division, School of Medicine, University
of Southampton, UK, whereas in the SCARF
cohort only the -519 A/G and -340 T/C genotypes
were analysed, and this was done at King Gustaf
V Research Institute, Karolinska Institutet at the
Karolinska University Hospital.
Coronary angiography
Coronary angiography has for a long time been
the golden standard for diagnosing CAD and
measuring extent and severity of the disease. The
cardiac catheterisation method rendered Werner
Forssmann, André Cournand and Dickinson
Richard the Nobel Prize in 1956 and the selective
coronary angiography came into routine use in the
60’s and 70’s141. Coronary angiography is a
radioangiographic method using iodine based
radioopaque contrast medium to visualize the
lumen of the arteries. A stenosis appears as narrow-
ing of the lumen of the coronary artery tree or
sudden interruption of the artery in case of occlu-
sions, a common finding in STEMI. In earlier years,
the images were stored on 35 mm cine films but
nowadays they are collected digitally and stored
on a server or on compact discs. The digital images
can then be interpreted by computerized algorithms.
Despite the usefulness of coronary angiography in
detecting stenoses and need for revascularization,
a crucial limitation of this method is the ”lumeno-
graphy”, the two-dimensional luminal imaging.
From angiography you cannot tell anything about
the vessel wall or the composition of the plaques
intruding into the lumen. In fact, it is shown that
substantial alterations in the vessel wall can occur
without any change to the inner lumen surface.
Thus, the vessel may look perfectly normal on the
angiographic images. Intravascular ultrasound
(IVUS) is a method imaging the vessel wall cross-
sectionally, in a histology-like fashion, and has been
developed in the late 80’s. The method is mainly
used for research. IVUS makes it possible, at least
to some extent, to discriminate between lipid-rich
and fibrous plaques in vivo.
QCA
Quantitative coronary angiography (QCA) is a
computerized method designed for analysing
coronary angiographies (Figure 4). In this thesis
(papers I and IV), the Medis QCA-CMS system
developed in Leiden, the Netherlands, has been
used. The intra- and inter-observer variability of
QCA has been addressed in several papers. The
QCA method has proved to be superior to visual
methods and hand-held calipers142.  Validation of
the QCA-CMS system has been performed by
several authors and the intra-measurement varia-
bility of the diameter stenosis was found to be 0.5-
1.0 ± 2.5-3.7% (± standard deviation (SD)) and
the SD of minimal lumen diameter (MLD)
measurements was 0.07-0.094 mm143-145.
In SCARF
Coronary angiograms were obtained, after intra-
coronary administration of glycerylnitrate (0.1 mg/
mL, 2.5 mL), using the Philips Integris H3000
angiographic system. The first 200 examinations
were stored on 36 mm cine film and the remaining
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43 on CD-ROM. Angiograms were analysed by
QCA (Medis QCA-CMS system). The coronary
artery tree was divided into 15 segments according
to American Heart Association (AHA) guide-
lines146. In each segment, MLD, reference diame-
ter, % diameter stenosis, mean segment diameter
(MSD), segment length, plaque area, segment area
and number of significant (>50%) stenoses were
registered.
Figure 4: QCA image of a stenosis in the right
coronary artery. The true borders of the lumen and the
computer estimated reference vessel borders are outlined.
The filled area is the plaque area. %-D, diameter stenosis;
%-A, area stenosis.
In TREOC
Coronary angiography was performed after ad-
ministration of 0.5 mg sublingual nitroglycerine
by using the transfemoral technique and 7F Judkin
diagnostic catheters. The angiographies were stored
on 35 mm cinefilm. Severity of CAD was quan-
tified as number of major coronary arteries with at
least one stenosis of more than 50% diameter
reduction (0-3 vessel disease) as assessed by one
experienced observer who was blinded to the
clinical characteristics and outcome of the patient.
Functional characterization of
promoter activity
Electrophoretic mobility-shift assays (EMSAs)
were performed in paper III to investigate whether
the different alleles (-519 A/G and -340 T/C) of the
MMP-1 haplotype studied were recognized by
nuclear proteins, and if so, whether the alleles
differed in the affinity to nuclear proteins. For each
allele, a double-stranded oligonucleotide probe of
24 bases up- and downstream of the respective
Transient transfection and reporter assays
Transient transfection and reporter assays were
performed in paper III to evaluate whether the
different haplotypes influenced the MMP-1 pro-
moter activity. Genomic DNA from the nine most
common haplotypes derived from the initial
sequencing analysis in paper III were used as
templates for generating the MMP-1 promoters by
PCR, and subsequently cloned into a TOPO PCR
cloning vector (Invitrogen). The promoters were
cloned from -1870bp to +42bp relative to the
transcriptional start site. The cloned MMP-1
promoter was sequenced to verify that there was
no misincorporation during PCR. The created
promoters were then subcloned into a plasmid
(pGL3-Basic Vector, Promega) containing a firefly
luciferase reporter gene. The resultant construct was
mixed with a plasmid (pRL-TK, Promega)
containing a renilla luciferase gene under the
EMSA
polymorphism was created and labelled with
radioactive 32P at the 5’ terminus. The sequences
of the probes were 5’-GCCATGGTGCTATCGC
AATAGGGTA/GCCAGGCAGCTTAACAAAG
GCAGAA-3’and 5’-GGTGTGTGGAGAAACC
TGTAGCACC/TTTATGACCATCAGAACCA
GTCTTT-3’ (polymorphisms in bold). The labelled
probe was incubated with nuclear protein extracts
from cultured human macrophages derived from
THP-1 cells, either alone, or with unlabeled specific
or non-specific competitor. DNA with bound
nuclear protein was separated from unbound DNA
on a polyacrylamide gel by electrophoresis. The
gel was read by autoradiography using a phospho-
imager (Fuji). Three independent experiments were
performed for each polymorphism.
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Real-Time RT-PCR
In the real-time reverse transcriptase (RT)-PCR
experiment performed in paper III, RNA was
extracted from atherosclerotic plaques removed
from patients undergoing carotid endarterectomy.
RNA was reverse transcribed to complementary
DNA (cDNA). Real-time PCR was performed in
duplicates in an ABI Prism 7700 Sequence
Detection System. PCR primers were designed
with the use of the Primer Express program
(Applied Biosystems), with the forward and reserve
primers placed in different exons. The MMP-1 real-
time RT-PCR results of different samples were
standardized for the amounts of RNA template and
efficiencies of reverse transcription, using the
housekeeping gene 36B4 (acidic ribosomal phos-
phoprotein PO subtype) as a reference, and relative
quantification was done by use of the 2-ΔΔCT
method147. The haplotype effects of the MMP-1
-519 A/G and -314 C/T polymorphisms on MMP-
1 mRNA levels were analysed using the THESIAS
program.
Statistical analyses
Statistical analyses were performed by using the
STATISTICA software, version 6.0 in paper I and
version 7.1 in papers II and IV (StatSoft inc, Tulsa,
OK). Results are presented either as mean ± SD or
as median, with the interquartile range in brackets.
For quantitative variables with a skewed distribu-
tion, data were log-transformed to achieve a normal
distribution before comparisons were done. Com-
parisons between two groups were made by the χ2
In paper IV, cytokine and MMP-1 data were
extremely skewed, and the non-parametric Mann-
Whitney U test was used for case-control com-
parisons whereas Spearman rank correlation
coefficients were computed to estimate interrela-
tions. A second analysis was done based on dicho-
tomised cytokine data: values above as opposed to
below detection level. The χ2 test was then used
for patient-control comparisons.
Associations of individual polymorphisms with MI
in papers I and III were examined by χ2 analysis.
In the haplotype analyses in paper III, a systematic
analysis of all possible combinations of polymor-
phisms to select the most informative haplotype
configuration in terms of predicting disease status
was performed using a method that calculates the
Akaike’s Information Criterion (AIC) values for
each haplotype model and then subtracts the
minimum AIC value obtained for each model over
all models explored, giving a rescaled AIC value
for each haplotype model148. The model with a re-
scaled AIC ≤ 2 and including the fewest poly-
morphisms is considered the best model. Because
the choice of model is based on AIC values, it
circumvents problems associated with methods
based on null-hypothesis testing, such as the
requirement of multiple testing correction. After
identifying the best model, the haplotype effects
of the polymorphisms in this model on MI risk
were analysed using the THESIAS program
(www.genecanvas.org), which implements the sto-
chastic-EM (Expectation-Maximization) algo-
rithm149. Haplotype effects on MI risk were adjusted
for age, gender, body mass index, smoking, chole-
sterol levels, statin treatment, hypertension and
diabetes.
control of a thymidine kinase promoter. Lipofection
with FuGENE 6 transfection reagent was used to
transfect cultured THP-1 human monocytic cells
with the respective plasmid mix. The transfected
cells were treated with phorbol 12-myristate 13-
acetate (PMA) to induce differentiation into
macrophages. At 36 hours after transfection, the
cells were lysed and the activities of the firefly
luciferase and renilla luciferase in the lysates were
measured with the use of a dual-luciferase assay
kit (Promega).  The ratio of firefly luciferase level
to renilla luciferase level was used as a measure of
the MMP-1 gene promoter activity. Three in-
dependent experiments in duplicate were per-
formed for each construct.
test for categorical variables and the unpaired
Student’s t-test for continuous variables.
A one-way analysis of variance (ANOVA) was
performed with the Scheffé post-hoc test and
planned comparisons when analysing serum
concentrations of MMP-3 in relation to genotype
and a factorial ANOVA was used when comparing
gender and patient and control groups. In paper II,
relationships of genotype or CAD severity groups
to serum MMP-3 concentration were assessed by
ANOVA. For comparisons between different time
points repeated measures ANOVA was used.
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RESULTS
MMP-3 and MMP-1 concentrations
in postinfarction patients (papers I
and IV)
Serum concentrations of MMP-3, in the SCARF
study (paper I), were lower amongst patients than
controls (16.2 ±6.9 vs. 19.2 ±8.2 ng/mL, p<0.0001,
Figure 5). Exclusion of subjects on statin treatment
(35% of patients) did not change this pattern (16.4
±7.3 vs. 19.2 ±8.2 ng/mL, p<0.0001). In contrast,
there was no difference in plasma MMP-1 concen-
tration between patients and controls (4.29 [3.98-
4.51] vs. 4.25 [3.98-4.54] ng/mL, p=0.70). Statin
treatment did not appear to influence the MMP-1
concentration. In addition, there were no differences
in either MMP-3 or MMP-1 concentrations be-
tween patients on different treatment, e.g. with and
without betablockers and angiotensin converting
enzyme (ACE) inhibitors, respectively. There was
no association between any medical treatment at
inclusion and serum MMP-3 concentrations.
Relationships of MMP-3 and MMP-1 concentra-
tions to established risk indicators for CAD were
explored separately in patients and controls. In
control subjects, but not in patients, serum MMP-
3 concentrations correlated significantly with both
systolic (r=0.14, p<0.01) and diastolic (r=0.18,
p<0.001) blood pressure, blood glucose (r=0.11,
p<0.05) and plasma triglycerides (r=0.13, p<0.05).
In patients, on the other hand, a negative correlation
was seen between serum MMP-3 concentration and
BMI (r=-0.16, p<0.01). Furthermore, serum MMP-
3 concentrations correlated significantly with cys-
tatin C in both groups but the correlation was
stronger in patients (r=0.27 p<0.0001) than in
controls (r=0.11 p<0.05).
The plasma MMP-1 concentration correlated with
BMI (r
s
=0.14, p<0.05), insulin (r
s
=0.30, p<0.05)
cystatin C (r
s
=0.18, p<0.05) and PAI-1 (r
s
=0.30,
p<0.05) in the patient group, whereas in the control
group the plasma MMP-1 concentration correlated
only with insulin (r
s
=0.25, p<0.05) and PAI-1
(r
s
=0.17, p<0.05).
MMP-3 concentration in acute MI
(paper II)
In the SCARF study, blood samples were collected
three months after the acute event. Concerns could
be raised that the MMP-3 level might be altered in
the very acute stage of MI, possibly higher, and
then, in the recovery phase, return to a lower level.
To elucidate this question we analysed the MMP-
3 concentrations also in a group of patients suffering
STEMI (the TREOC study), in which we had
access to blood samples drawn at several time
points during and after the acute stage of MI.
Interestingly, in the TREOC study we found a
significant increase in serum MMP-3 concentration
at three months compared with at admission and
at 48 hours (19.5 [14.4-24.7] vs. 15.5 [10.5-21.8]
ng/mL, p<0.001 and 14.7 [9.9-23.8] ng/mL,
p<0.001, respectively). Furthermore, there was no
significant change in serum MMP-3 concentration
during the first 48 hours.
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Figure 5: Serum MMP-3 concentration in patients and
controls in the SCARF study (paper I). Mean and 95%
confidence intervals denoted by bars.
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MMP-3 and MMP-1 concentrations
and angiographic score (papers I, II
and IV)
In the SCARF study there were no significant
correlations between serum MMP-3 concentration
and angiography measurements obtained by QCA
in the entire patient group, or amongst male patients
separately. In female patients, however, a negative
correlation (r= -0.39, p<0.05) was found with
plaque area. The corresponding association in male
patients was non-significant (r=0.02).
The TREOC study, on the other hand, showed that
the serum MMP-3 concentration at three months
increased with severity of CAD, and the differences
were statistically significant between patients with
1- and 2-vessel disease (p=0.02), and patients with
1- and 3-vessel disease (p<0.001, Figure 6).
There were no differences in extension and severity
of CAD according to MMP-3 -1612 5A/6A geno-
type, neither in SCARF, nor in the TREOC study.
Plasma MMP-1 concentrations showed no
significant correlations with the QCA measure-
ments of CAD severity amongst patients.
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Figure 6: Serum MMP-3 concentration increases with the number of diseased vessels in the TREOC study
(paper II). Logarithm of serum MMP-3 at the three months follow-up visit on Y-axis. Mean and 95% confidence
interval denoted by bars.
MMP-3 genotype and MMP-3
concentration (papers I and II)
In the SCARF study population as a whole, patients
and controls analysed together, the distribution of
MMP-3 -1612 5A/6A genotype was 26% (5A/5A),
46% (5A/6A) and 28% (6A/6A), respectively,
giving a 6A-allele frequency of 0.51. There was a
clear association between MMP-3 -1612 5A/6A
genotype and serum MMP-3 concentration, with
the presence of one or two copies of the 6A-allele
being associated with a graded increase in serum
MMP-3 concentration. Accordingly, in all parti-
cipants analysed together, serum MMP-3
concentrations were lowest in 5A/5A homozygotes
(13.3 ±5.7 ng/mL), intermediate in 5A/6A
heterozygous individuals (17.5 ±6.5 ng/mL) and
highest amongst 6A/6A homozygotes (22.1 ±8.7
ng/mL, p<0.0001). The allelic dose-dependent
effect was seen in both groups and was even more
pronounced among control subjects (Figure 7).
The clear allelic dose-dependent result was sur-
prising as we had expected the 6A/6A homo-
zygotes to have the lowest levels according to in
vitro experiments showing the 6A-allele to be
associated with reduced expression48. To confirm
this result, we performed this analysis in the second
cohort of MI patients, the TREOC study.
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In the TREOC study, a total of 43 patients (26%)
were 5A/5A homozygotes, 79 (48%) were hetero-
zygotes and 42 (26%) were 6A/6A homozygotes,
giving a 6A-allele frequency of 0.50. The graded
increase in serum MMP-3 concentration according
to number of 6A-alleles was confirmed at all time
points (p<0.001 in ANOVA, Figure 8). Serum
MMP-3 distribution according to genotype at three
months revealed 5A homozygotes to have the
lowest levels (14.1 [10.2-18.8] ng/mL), hetero-
zygotes to have intermediate levels (19.6 [15.0-
24.4] ng/mL) and 6A homozygotes to have the
highest serum MMP-3 levels (24.0 [20.1-32.3] ng/
mL, p<0.001 for comparisons between all groups).
Gender and MMP-3 and MMP-1
concentrations (papers I, II and IV)
There was a striking gender difference pre-
dominantly in MMP-3 but also in MMP-1 con-
centrations in both cohorts analysed. In the SCARF
study, a gender difference in serum MMP-3
concentrations was present (Figure 9) both among
patients and control subjects (17.5 ±6.7 ng/mL in
male patients vs. 9.1 ±3.3 ng/mL in female patients,
p<0.0001; 21.0 ±7.6 ng/mL in male controls vs.
10.1 ±3.5 ng/mL in female controls, p<0.0001).
Gender explained 22% of the difference in serum
MMP-3 concentration using a stepwise regression
model including the genotype effect. The gender
difference in serum MMP-3 concentration was
confirmed in the TREOC study where female
patients had significantly lower serum concen-
trations of MMP-3 than male patients at the three
months follow-up visit (14.8 [9.4-20.8] vs. 19.9
[16.0-26.9] ng/mL, p<0.0001, Figure 10). The
effect of gender was significant at all three time
points in TREOC and for all MMP-3 -1612
5A/6A genotypes in both SCARF and TREOC.
Plasma levels of MMP-1 exhibited a gender
difference as well. Women in the SCARF study
had lower MMP-1 concentration than men when
pooling patients and controls (4.16 [3.90-4.46] vs.
4.29 [4.00-4.54] ng/mL, p<0.05). Analysing the
two groups separately revealed the gender
difference to be statistically significant in the
control group (4.08 [3.91-4.38] ng/mL in women
vs. 4.26 [4.00-4.56] ng/mL in men, p<0.05) but
not in the patient group (4.19 [3.89-4.53] ng/mL
in women vs. 4.31 [4.00-4.50] ng/mL in men,
p=0.20).
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Figure 8: Serum MMP-3 concentration increases with
number of 6A-alleles in the TREOC study (paper II).
Logarithm of serum MMP-3 at the three months follow-
up visit on Y-axis. Mean and 95% confidence intervals
denoted by bars.
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Figure 7: Serum MMP-3 concentration increases with
the number of 6A-alleles both in patients and controls
in the SCARF study (paper I). Mean and 95% confi-
dence intervals denoted by bars.
Identification of polymorphisms in
the MMP-1 gene (paper III)
To search for naturally occurring, common se-
quence variants in the MMP-1 gene, we sequenced
the promoter, exons, and intron-exon junctions of
the gene in 30 unrelated Caucasian individuals. In
the promoter region, SNPs were identified at
positions -1607 (G/GG, i.e. G insertion/deletion),
-839 (G/A), -755 (G/T), -519 (A/G), -422 (T/A),
-340 (T/C) and -320 (T/C). In the coding region,
only two polymorphisms were identified, neither
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MMP-1 haplotype effect on risk of
MI (paper III)
No significant difference in genotype distribution
of individual polymorphisms was detected between
the two groups in the SAS cohort. A systematic
analysis of all possible combinations of the
polymorphisms in relation to MI was performed,
and the analysis showed that the best model in terms
of predicting MI status was one that consisted of
the -519 A/G and -340 T/C polymorphisms.
Haplotype analysis based on these two poly-
morphisms showed that the haplotype frequencies
were significantly different between the MI and
non-MI groups (χ2=16.48 with 3 df, p<0.001, Table
8). Compared with the A
-519
-T
-340
 haplotype, both
the A
-519
-C
-340
 and G
-519
-T
-340
 haplotypes conferred
a protective effect against MI (OR=0.68 [0.52–
0.88], p=0.004, for A
-519
-C
-340
; OR=0.71 [0.56–
0.89], p=0.003 for G
-519
-T
-340
, the common OR
associated with these two haplotypes being
OR=0.70 [0.57–0.86], p=0.0007, Table 8), whereas
the G
-519
-C
-340
 haplotype was associated with an
increased risk of MI (OR=1.94 [1.15–3.28],
p=0.013, Table 8).
To verify these findings, the SCARF cohort was
genotyped for the two polymorphisms included in
the haplotype analysis. The result confirmed a
protective effect of the A
-519
-C
-340
 and G
-519
-T
-340
Experimental evaluation of MMP-1
promoter haplotypes (paper III)
Effects of MMP-1 polymorphisms on
nuclear protein binding
The EMSAs for the -519 A/G and -340 T/C
polymorphisms indicated the presence of specific
DNA-nuclear protein interactions for both poly-
morphisms. For the -519 A/G polymorphism, a
DNA-protein complex was detected in assays using
a probe corresponding to the A
-519
 allele but not in
assays using a probe corresponding to the G
-519
allele. For the -340 T/C polymorphism, a DNA-
protein complex was detected when using a probe
corresponding to the C
-340
 allele but not when using
a probe corresponding to the T
-340
 allele. (Figure 2
in paper III)
Effects of MMP-1 haplotypes on
promoter activity
To investigate whether the -519 A/G and -340 T/C
polymorphisms had a functional effect, we examin-
of which generated changes in the amino acid
sequence. The subsequent studies were therefore
focused on the promoter polymorphisms.
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Figure 9: Higher serum MMP-3 concentration in men
than in women in the SCARF study. Mean and 95%
confidence intervals denoted by bars.
Figure 10: Higher serum MMP-3 concentration in
men than in women in the TREOC study. Logarithm
of serum MMP-3 at the three months follow-up visit on
Y-axis. Mean and 95% confidence intervals denoted by
bars.
haplotypes (OR=0.72 [0.54–0.94], p=0.02, for
A
-519
-C
-340
versus A
-519
-T
-340
;OR=0.68 [0.52–0.89],
p=0.005, for G
-519
-T
-340
versus A
-519
-T
-340
; and
OR=0.70 [0.55-0.89], p=0.003, for A
-519
-C
-340
+
G
-519
-T
-340
versus A
-519
-T
-340
; Table 8), and an
increased risk for the G
-519
–C
-340
 haplotype
(OR=1.54 [0.97–2.46], p=0.07, for G
-519
–C
-340
 ver-
sus A
-519
-T
-340
, Table 8).
   35MMPs in coronary artery disease
Ta
bl
e 
8.
  H
ap
lo
ty
pe
 e
ff
ec
ts
 o
f t
he
 M
M
P
-1
 -5
19
 A
/G
 a
nd
 -3
40
 T
/C
 p
ol
ym
or
ph
is
m
s 
on
 r
is
k 
of
 m
yo
ca
rd
ia
l i
nf
ar
ct
io
n
O
R
, o
dd
s 
ra
tio
; C
I, 
co
nf
id
en
ce
 in
te
rv
al
.
T
he
 a
na
ly
se
s 
sh
ow
ed
 th
at
 th
er
e 
w
as
 n
o 
si
gn
if
ic
an
t d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
G
-5
19
–T
-3
40
 a
nd
 A
-5
19
–C
-3
40
 h
ap
lo
ty
pe
s 
in
 re
la
tio
n 
to
 M
I r
is
k
H
ap
lo
ty
pe
H
ap
lo
ty
pe
 f
re
qu
en
cy
H
ap
lo
ty
pe
 e
ff
ec
ts
 o
n 
ri
sk
 o
f M
I
H
ap
lo
ty
pe
 e
ff
ec
ts
 o
n 
ri
sk
 o
f M
I
(h
om
og
en
eo
us
 e
ff
ec
ts
 o
f A
-5
19
-C
-3
40
 a
nd
 G
-5
19
-T
-3
40
)
M
I
C
on
tr
ol
SA
S
gr
ou
p
gr
ou
p
A
-5
19
–T
-3
40
0.
43
0.
36
re
fe
re
nc
e 
ha
pl
ot
yp
e
re
fe
re
nc
e 
ha
pl
ot
yp
e
A
-5
19
–C
-3
40
0.
19
0.
24
O
R
=0
.6
8 
(9
5%
 C
I=
0.
52
-0
.8
8)
, p
=0
.0
04
G
-5
19
–T
-3
40
0.
31
0.
37
O
R
=0
.7
1 
(9
5%
 C
I=
0.
56
-0
.8
9)
, p
=0
.0
03
G
-5
19
–C
-3
40
0.
07
0.
03
O
R
=1
.9
4 
(9
5%
 C
I=
1.
15
-3
.2
8)
, p
=0
.0
13
O
R
 =
1.
93
 (9
5%
 C
I=
1.
14
–3
.2
6)
, p
=0
.0
14
SC
A
R
F
A
-5
19
–T
-3
40
0.
40
0.
34
re
fe
re
nc
e 
ha
pl
ot
yp
e
 re
fe
re
nc
e 
ha
pl
ot
yp
e
A
-5
19
–C
-3
40
0.
22
0.
27
O
R
=0
.7
2 
(9
5%
 C
I=
0.
54
–0
.9
4)
, p
=0
.0
16
G
-5
19
–T
-3
40
0.
27
0.
34
O
R
=0
.6
8 
(9
5%
 C
I=
0.
52
–0
.8
9)
, p
=0
.0
05
G
-5
19
–C
-3
40
0.
11
0.
05
O
R
=1
.5
4 
(9
5%
 C
I=
0.
97
–2
.4
6)
, p
=0
.0
70
 O
R
=1
.5
3 
(9
5%
 C
I=
0.
96
 - 
2.
44
)  
p=
0.
07
4
O
R
=0
.7
0 
(9
5%
 C
I=
0.
57
–0
.8
6)
, p
=0
.0
00
7
}
O
R
=0
.7
0 
(9
5%
 C
I=
0.
55
 - 
0.
89
)  
p=
0.
00
3
}
36 Ann Samnegård
Influence of circulating inflammatory
cytokines (paper IV)
Blood samples for the biochip immunoassay were
missing for 26 patients and 12 control subjects.
Plasma concentrations of several cytokines (IL-2,
IL-6, IL-8, and TNF-α) were higher in patients
compared with controls (Table 9). More than 50%
of the individuals had undetectable plasma levels
of five of the cytokines (IL-1α, IL-1β, IL-4, IL-10
and IFN-γ ). For evaluation of these cytokines we
In contrast, the MMP-1 concentration was found
to correlate more strongly and mostly positively
with several cytokines (Table 10). The most con-
sistent correlations were seen with IL-10 (r
S
=0.27,
p<0.05 in the combined sample) and IL-4 (r
S
=0.20,
p<0.05 in the combined sample). For IL-6 and
TNF-α significant correlations were accounted for
by the controls (r
S
=0.23, p<0.05 for both). Weaker
but still significant positive correlations were ob-
served with IL-1α (r
S
=0.15, p<0.05) and MCP-1
(r
S
=0.14, p<0.05) in patients and with IL-1β
(r
S
=0.14, p<0.05) in controls. Also, a weak inverse
correlation was found with IL-2 (r
S
=-0.16, p<0.05)
in the patient group. Of note, MMP-1 correlated
inversely with IL-8 in patients (r
S
=-0.15, p<0.05)
but positively in controls (r
S
=0.11, p<0.05).
Patients (n=361) Controls (n=375) p-value
IL-1α (pg/mL) 0.00 (0.00-0.91) 0.00 (0.00-0.91) ns
IL-1β (pg/mL) 0.05 (0.00-0.81) 0.00 (0.00-0.26) <0.05
IL-2 (pg/mL) 5.68 (0.00-7.09) 1.51 (0.00-6.17) <0.0001
IL-4 (pg/mL) 0.00 (0.00-1.49) 0.00 (0.00-1.50) ns
IL-6 (pg/mL) 1.31 (0.65-2.75) 0.59 (0.16-1.84) <0.0001
IL-8 (pg/mL) 3.72 (2.27-5.75) 1.76 (0.88-3.43) <0.0001
IL-10 (pg/mL) 0.00 (0.00-0.39) 0.00 (0.00-0.44) ns
IFN-γ  (pg/mL) 0.00 (0.00-0.00) 0.00 (0.00-0.00) ns
TNF-α (pg/mL) 3.92 (3.23-4.81) 3.48 (2.86-4.23) <0.0001
MCP-1 (pg/mL) 160.2 (131.9-199.5) 159.2 (127.8-198.2) ns
Table 9. Circulating inflammatory cytokines in patents and controls
Values are median (interquartile range). Significance level in Mann-Whitney U test.
ed the promoter activity of MMP-1 haplotypes in
driving the expression of a luciferase reporter gene
in transiently transfected THP-1 cell-derived hu-
man macrophages. Compared with the haplotypes
encompassing both the A
-519
and T
-340
 alleles, the
haplotypes encompassing both the A
-519
and C
-340
alleles and those encompassing both the G
-519
 and
T
-340
 alleles had lower promoter activity (p<0.01,
Table 3 in paper III).
Haplotype effects on MMP-1 expression
MMP-1 mRNA levels in atherosclerotic plaques
from patients with different haplotypes were
estimated using the real-time RT-PCR method. The
A
-519
-C
-340
 and G
-519
-T
-340
 haplotypes were associated
with lower MMP-1 expression as compared with
the A
-519
-T
-340
 haplotype. The relative mRNA levels
were 0.205 (95% CI 0.064-1.532) for A
-519
-C
-340
and 0.230 (95% CI 0.029-1.844) for G
-519
-T
-340
(p=0.033, Figure 3 in paper III). The rare G
-519
-
C
-340
haplotype was not present in the patients
studied.
dichotomised the data as described in Subjects and
methods, Statistical analyses. When comparing
patients and controls, a trend towards a lower
proportion of individuals with a detectable concen-
tration of IL-10 was found in the patient group (39%
vs. 46%, p=0.086) (Table 2 in paper IV). Con-
versely, a trend towards a higher proportion of
individuals with detectable IL-1β levels was
encountered in the patient group (50% vs. 44%,
p=0.082).
MMP-3 showed weak inverse correlations with
IL-6 (r
S
=-0.10, p<0.05) and IL-8 (r
S
=-0.07, p<0.05)
when patients and controls were pooled, but the
correlations were no longer statistically significant
when the two groups were analysed separately
(Table 10).
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MMP-3 MMP-1
P+C Patients Controls P+C Patients Controls
IL-1α -0.01 0.03 -0.06 0.09* 0.15* 0.03
IL-1β -0.03 -0.05 0.03 0.10* 0.06 0.14*
IL-2 -0.06 -0.03 -0.02 -0.10* -0.16* -0.04
IL-4 0.00 0.03 -0.03 0.20* 0.23* 0.17*
IL-6 -0.10* -0.07 -0.01 0.16* 0.09 0.23*
IL-8 -0.07* -0.04 0.03 -0.02 -0.15* 0.11*
IL-10 0.03 0.06 -0.01 0.27* 0.24* 0.30*
IFN-γ -0.04 0.02 -0.08 -0.01 -0.00 -0.02
TNF-α 0.02 0.05 0.07 0.14* 0.03 0.23*
MCP-1 0.05 0.06 0.05 0.09* 0.14* 0.03
Table 10: Spearman rank correlations between MMP-3 and MMP-1 concentrations and inflammatory cytokines
* p<0.05, figures in bold, P+C=patients and controls
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GENERAL DISCUSSION
The focus of this thesis is the evaluation of the
roles of MMP-3 and MMP-1 in coronary artery
disease and myocardial infarction, and their poten-
tial modulation by inflammation. This was perfor-
med by genetic analyses of known and novel
polymorphisms in the MMP-3 and MMP-1 genes,
biochemical analyses of circulating levels of MMP-
3, MMP-1 and various cytokines, and angiographic
analyses of the extent and severity of CAD.
MMP-3 genotype-phenotype relation
Several case-control studies have been conducted
to evaluate the association between the MMP-3
-1612 5A/6A promoter polymorphism and the risk
of suffering MI (Table 3). Five studies out of eight
concluded that the 5A-allele is associated with a
higher risk of MI80,96-99, whereas one study, by far
the largest one, indicated that the 6A-allele is
associated with a higher risk100. In two studies there
was no difference according to genotype88,95. In the
study reported in paper I, we genotyped a well-
defined case-control cohort comprising 387 post-
infarction patients and 387 control subjects
(SCARF) for the MMP-3 -1612 5A/6A promoter
polymorphism. The allele frequency did not differ
significantly between the two groups, yielding no
excess risk of MI for either allele. Importantly, our
study was not designed to detect differences in
allele frequencies between the groups, since it was
too small to detect minor differences in risk of MI.
Furthermore, we did not detect any difference in
the extent or severity of CAD between genotype
groups. In the literature there are ten studies
addressing this latter question, or progression of
CAD using repeated angiographies (Table 2). Of
these studies, eight showed that the 6A-allele is
associated with more severe disease, as evaluated
by angiography79,80,84,88-92, whereas one proposed the
5A-allele94. However, the largest study detected no
differences93. Thus, our study could not confirm
the notion that the 5A-allele increases the risk of
MI whereas that the 6A-allele promotes progres-
sion of atherosclerosis150,151. Interestingly, when
reviewing the published studies on these issues,
the largest ones on risk of MI and on CAD severity,
respectively, presented the deviating results. In
addition, in a large family-based case-control study,
no association between MMP-3 -1612 5A/6A
genotype and MI or CAD could be detected108. In
fact, the problem of underpowered genotype-
phenotype association studies is widespread, and
one cannot exclude a publication bias where
smaller studies presenting a genotype-specific
effect are reported whereas those that failed to
demonstrate an effect may not have been published.
To finally assess the possible association of the
MMP-3 -1612 5A/6A polymorphism with MI and
CAD, we need larger, well-conducted longitudinal
cohort studies or prospective population-based
studies with refined definitions of the phenotype.
Functional in vitro studies on the MMP-3 -1612
5A/6A promoter polymorphism have shown the
5A-allele to be associated with increased ex-
pression of MMP-348,81. Against this background,
we expected the serum MMP-3 concentrations to
be higher in individuals carrying the 5A-allele. In
contrast, our results showed a very clear increase
in serum MMP-3 concentration with increasing
numbers of 6A-alleles (paper I). In a study of
patients with rheumatoid arthritis, Mattey et al. had
the same paradoxical finding83. In order to further
elucidate this issue, we performed genotype
analysis in the TREOC study as reported in paper
II. This second study replicated our results in
SCARF. In addition, White and co-workers
presented similar results obtained in CAD patients
at the American Heart Association Scientific
Sessions 200584. To the best of my knowledge, no
one has reported homozygotes for the 5A-allele to
have higher levels of circulating MMP-3 than
heterozygotes and/or 6A homozygotes, whereas
there are three studies reporting no difference
between genotypes85-87. These conflicting findings
between in vitro and in vivo studies are difficult to
explain, but the results are very clear and convin-
cing, as they have been reproduced in five different
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study groups, counting the patient and control
groups of the SCARF cohort as two independent
samples. Importantly, the serum MMP-3 con-
centration appears to be related to MMP-3 gene
expression and not to altered clearance of the
protein since the serum concentrations are asso-
ciated with the promoter polymorphism.
It may be argued that the circulating levels have
little to do with what is occurring within the vessel
wall as MMPs may bind to connective tissue and
be retained within the ECM152. However, it would
be expected that leakage of protein into the blood
stream would be correlated with expression of the
protein. It cannot be excluded that there are other
sources of circulating MMP-3 than the vessel wall.
Also, the impact of the promoter polymorphism
may be different during inflammatory conditions,
which are present in the atherosclerotic vessel wall.
The functional experiment of Ye et al. was
performed in vitro, and the cells may have altered
their behaviour when extracted from their original
environment48. However, the experiment of Medley
et al. where MMP-3 mRNA levels were higher in
the 5A homozygotes, as measured in skin biopsies,
argues against this explanation81. This result was
replicated in aortic samples from a different, though
rather small (n=7), study group to confirm that cell
type does not influence the expression.
Circulating MMP-3 and MMP-1
Several MMPs have been indicated to be expressed
in atherosclerotic tissue but not in non-affected
vessels, suggesting an essential role in athero-
sclerosis38-40. Efforts to reinforce this conclusion
by analysing circulating levels of MMPs in case-
control studies have not reached consistent results,
and most of the studies included less than 100
individuals55-59,61,153. We investigated MMP-3 and
MMP-1 in the SCARF case-control study
consisting of a total of 774 individuals. The serum
MMP-3 concentration was found to be lower in
the patient group as compared to the control group
(paper I), whereas the plasma MMP-1 con-
centrations did not differ between the groups (paper
IV). Importantly, the blood samples for these
analyses were drawn three months after the acute
event when the acute inflammation due to myo-
cardial damage had subsided. The results therefore
could be regarded as reflecting the resting in-
flammatory state of the patient. A problem inherent
in this approach is the potential influence of the
medication that the patients, but obviously not the
control subjects, received during the three months
preceding blood sampling. Experimental studies
have for example suggested that statins reduce the
expression of MMP-1154, MMP-2155, MMP-3156 and
MMP-9157-160. Only 35% of the patients in SCARF
were on lipid-lowering therapy as this study was
conducted before the widespread use of statins in
secondary prevention. However, the levels of
neither MMP-3 nor MMP-1 differed between
patients on statins and those who had not received
this therapy. In addition, excluding patients on
statins from the case-control analysis of MMP-3
and MMP-1 did not change the initial results
reported in papers I and IV, nor did ACE-inhibitors
influence the results. Similar analyses of aspirin
and betablockers are hazardous as the vast majority
of the patients were constantly on these medi-
cations, but no difference between patients with
and without these medications were detected.
As MMPs are indicated to be involved in plaque
rupture, it is plausible that the MMP-3 and MMP-
1 concentrations might have been higher in the
acute stage of MI. To evaluate this issue, in the
case of MMP-3, we measured the serum MMP-3
concentration in the TREOC cohort of STEMI
patients where we had blood samples available both
from the acute stage and the three months follow-
up visit. The analysis revealed that the MMP-3
concentration is actually lower in the acute stage,
0 and 48 hours after admission, than in the recovery
period, three months after the index event (paper
II). This is in contrast to two earlier reports
published on the levels of MMP-3 in the acute
conditions of CAD as both claimed higher
concentrations of MMP-3 in ACS than in stable
CAD patients and also in comparison with
controls56,57. In both these studies, there were 20
individuals, or less, included in each study group.
Also, in one of the studies, the difference was only
seen in coronary sinus blood whereas no difference
was detected in blood drawn from the aortic root56.
In addition, none of the study groups were followed
over time. Another study of stable angina pectoris
demonstrated higher levels in patients than in
controls58. In contrast, other studies of stable CAD
or risk factor conditions such as hyperlipidemia
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and type 2 diabetes, showed lower concentrations
of MMP-3 in affected subjects55,59,60. These
diverging study results may of course indicate that
the circulating levels of MMP-3 are not related to
acute MI or other manifestations of CAD, but
histopathological studies of atherosclerotic plaques
have clearly indicated MMP-3 to be present in
affected but not in normal vessels, indicating a role
of MMP-3 in the pathogenesis of athero-
sclerosis38,39. Furthermore, most of these studies
are quite small in terms of numbers of participants.
In fact, both our studies, detecting lower MMP-3
concentrations in MI patients and during the acute
stage of MI, are larger than the previously per-
formed.
Clearance of MMPs is of course a process that can
influence the circulating levels of MMP-3 and
MMP-1. MMP clearance is quite unexplored, and
little is known about the mechanisms. The low-
density lipoprotein receptor-related protein (LRP)
is proposed to contribute to clearance of at least
some of the MMPs161. In this context it is important
to note that the circulating MMP-3 concentration
is clearly influenced by the MMP-3 -1612 5A/6A
promoter polymorphism suggesting that MMP-3
levels reflect the transcriptional activity rather than
degradation or clearance processes.
On the assumption that circulating levels of MMPs
reflect the amount of MMPs in the vessel wall, the
finding of lower MMP-3 concentration in the acute
stage of MI as well as in postinfarction patients
compared with control subjects speaks against
elevated MMP-3 concentrations in atherosclerotic
tissue being an important feature of fibrous cap
weakening and plaque rupture. This uncertainty is
strengthened by recent studies in MMP-3 deficient
mouse models. Two studies of apoE/MMP-3
double knockout mice have demonstrated larger
cross-sectional atherosclerotic plaque areas43, 44,
with a lower content of SMCs and an increased
number of buried fibrous layers, features of a less
stable plaque43.
Studies on circulating MMP-1 concentrations in
relation to MI and stable CAD seem to be as
contradictory as the studies on MMP-3. In two
studies, MMP-1 has actually been undetectable65,66,
while other studies have shown either higher
MMP-1 concentrations56,72, notably only in ACS
patients, or no difference in case-control
studies64,68,70,74. Several studies have detected a
transient increase in the MMP-1 concentration
during the initial phase of MI, but MMP-1 appears
to return to baseline concentration already within
the first month69,71,73. Our result of no difference in
plasma MMP-1 concentration between post-
infarction patients and controls at three months after
the index event is in agreement with these previous
studies (paper IV).
Coronary angiography and MMPs
Coronary angiography is still the routine method
to detect hemodynamically significant stenoses in
the coronary circulation. In the future, it is likely to
be replaced by multi-slice computer-assisted tomo-
graphy (CT) or magnetic resonance imaging (MRI),
at least for the purpose of ruling out significant
CAD162. Today it is widely recommended to per-
form coronary angiography followed by appropri-
ate intervention when needed, in patients presen-
ting with ACS, and also in most instances of stable
CAD163.  In most of the studies discussed above,
routine coronary angiography was performed, but
no correlation was found between number of
diseased vessels and MMP-3 concentration56,58.
Similar results were noted for MMP-156,64.
The only angiographic observation reported to
correlate with MMP-3 concentration was signs of
ectasia or aneurysm. Finkelstein et al. reported
higher MMP-3 concentrations in patients with only
focal signs of coronary ectasia whereas patients
with generalized ectasia had lower concentra-
tions164. In contrast, Tengiz et al. detected higher
MMP-3 concentrations in patients with CAD and
coronary aneurysm as compared with patients with
CAD but no coronary aneurysm153. The patho-
physiology of aneurysm formation in coronary
arteries is probably slightly different from that of
the obstructive changes characteristic of classic
CAD, even though atherosclerosis is apparent also
in aneurysmal disease. In this context, our finding
of increasing levels of MMP-3 with increasing
numbers of diseased major coronary arteries in
paper II is very interesting as this is the first study
to report a possible correlation between the circula-
ting MMP-3 concentration and extent of CAD. On
the other hand, the results in the SCARF study
(paper I) were not entirely clear as there were in-
creasing MMP-3 concentrations from 0- to 2-vessel
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disease whereas patients with 3-vessel disease had
again lower concentrations, which did not differ
significantly from the levels of patients with 0-
vessel disease. Like others, we did not detect any
correlation of MMP-1 levels with angiographic
measurements (paper IV).
The studies on the MMP-3 -1612 5A/6A promoter
polymorphism have generally claimed that the
extent of CAD is higher in carriers of the 6A-allele,
assuming a relation to lower levels of MMP-3,
consistent with the gene expression study of Ye et
al.48, but the circulating MMP-3 was actually not
measured. In our studies we have shown that the
serum MMP-3 concentration is higher in carriers
of the 6A-allele, thus suggesting that higher MMP-
3 concentrations are associated with more extensive
CAD. Contradictory to this, however, is the finding
of an inverse correlation between MMP-3 concen-
tration and plaque area in women (paper I), but as
will be discussed, there are several gender differen-
ces in this field. It should also be stressed that
coronary angiography is not the best method to
estimate the true plaque area as it is only the area
of the plaque that is protruding into the lumen that
is measured. IVUS is in most respects a superior
method to measure true plaque area, but at the time
when the SCARF study was conceived and con-
ducted this method was not available in our
institution.
Gender differences in MMP-3 and MMP-1
Both MMP-3 and MMP-1 levels were found to be
lower in women than in men; for MMP-3 concen-
tration there was a striking, almost two-fold,
difference (papers I and II). Gender differences in
atherosclerosis and CAD are well-known since
decades, but the underlying causes are not fully
understood. These differences may be mediated by
the sex steroid hormone receptors, which when
activated, act as transcription factors, modulating
gene expression through binding to DNA response
elements. There are many indications that oestrogen
plays a protective role in pre-menopausal women,
but the belief in hormone replacement therapy as
the rescuer to all women came to nought when
tested in prospective randomised trials118,119. This
was disappointing and surprising as much of the
molecular and cellular knowledge about the effects
of oestrogen pointed towards a benefit of oestrogen
substitution117,165.
In a study of cultured human aortic SMCs, testo-
sterone was found to increase both transcription
and translation of the MMP-3 gene, rendering a
two-fold increase in protein levels as compared to
cells cultured with the combination of 17 β-
oestradiol and progesterone131. In addition, cells
cultured with the female sex hormones produced
an elastin/collagen ratio that was essentially higher
than in cells cultured with testosterone. In another
study of cultured osteoarthritic chondrocytes, the
secretion of MMP-1 was significantly reduced by
17β-oestradiol, also when stimulated by a low
concentration of TNF-α, but not IL-1β, whereas
in this study there was no effect on MMP-3 secre-
tion130. Whether these mechanisms demonstrated
in vitro are responsible for the observed gender
differences needs to be proven.
The sex difference in circulating MMP-3 levels
revealed in the SCARF study (paper I) corre-
sponded in terms of magnitude with the in vitro
studies, whereas the difference in TREOC was less
pronounced but still significant (paper II). The
gender difference in circulating levels of MMP-3
was first reported by Manicourt et al. investigating
osteoarthritis and healthy controls who described
a two-fold higher serum concentration of MMP-3
in males as compared to females166. In that study,
the serum MMP-3 concentration increased with
age, a correlation that we could not confirm in the
SCARF cohort, but which was evident in the
TREOC cohort. These diverging results may pos-
sibly be due to the upper age limit of 60 years in
the SCARF cohort. Increased MMP-3 concentra-
tion in female healthy controls has also been re-
ported by Zucker et al.49, whereas Beaudeux et al.
did not detect any gender difference in hyper-
lipidemic, otherwise healthy subjects61. In contrast
to our finding in paper IV, Manicourt et al. did not
detect any gender difference in serum MMP-1
level. Even though both sexes are included in the
majority of the studies exploring circulating levels
of MMPs, very few report the results according to
gender.
MMP-1 haplotype effect
Association studies of candidate genes and their
polymorphisms in atherosclerotic diseases have up
to recently focused on single polymorphisms. Since
these conditions are really complex and multi-
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factorial, this approach seems to be unlikely to
succeed in determining genetic susceptibility76.
Haplotype analysis of interrelated polymorphisms
within a single gene or in closely related genes has
emerged as a refined method to explore genetic
influence on disease processes. Haplotype analysis
may reveal associations that are not obvious when
analysing the different polymorphisms indivi-
dually167-169. Our study of the MMP-1 gene
polymorphisms (paper III) constitutes a good
example as none of the seven identified promoter
polymorphisms were individually associated with
increased risk of MI whereas the combinations of
two of the polymorphisms, -519 A/G and -340
T/C, were associated with the risk of MI. In our
study, the -1607 G/GG polymorphism did not
appear as a predictor of the risk of MI, neither in
isolation, nor in the haplotype analysis. This might
be explained by the close linkage between the
-1607 G/GG and -519 A/G polymorphisms114.
The fact that haplotype analyses was superior to
individual SNP genotype analyses as regards
prediction of risk in our study could possibly be
due to the complex interactions between the
promoter region and the transcription complex. The
different polymorphisms do not act independently,
but rather interact in modifying binding sites for
transcription factors. In addition, different poly-
morphisms may not be simply additive but rather
modulate each other’s binding properties as
proposed by Terry et al. in a study of haplotype
effects in IL-6 gene transcription170. Another ex-
planation could be that haplotypes are more likely
to show linkage disequilibrium with an as yet
unknown causal gene variant171.
Functional studies of the haplotypes proposed in
paper III to be associated with MI supported the
statistical finding of a divergent risk of MI. As
indicated by EMSAs, both the -519 A/G and -340
T/C polymorphisms seem to influence the capacity
of binding nuclear proteins to the promoter region.
Efforts to identify the nuclear proteins involved in
the DNA-protein complexes were unsuccessful,
indicating that the transcription factors in question
are probably not present in the current databases.
Nevertheless, this finding suggests the -519 A/G
and -340 T/C polymorphisms role of alter the
transcription of the MMP-1 gene. This suggestion
was strengthened by the transient transfection
studies where the firefly luciferase reporter gene
was less expressed by the A
-519
-C
-340
 and G
-519
-T
-340
promoter haplotypes than by the A
-519
-T
-340
 promoter
haplotype. In addition, real-time RT-PCR of athero-
sclerotic carotid plaques revealed lower levels of
MMP-1 mRNA in plaques from patients with the
A
-519
-C
-340
 and G
-519
-T
-340
 haplotypes than in plaques
from patients with the A
-519
-T
-340
 haplotype. No
plaque from a carrier of the G
-519
-C
-340
 haplotype
was eligible. These experimental studies indicate
a decreased MMP-1 expression in lower risk haplo-
types, coherent with the hypothesis of increased
collagenolysis in the vulnerable atherosclerotic
plaque contributing to plaque rupture40.
Inflammation and MMPs
In the past decades, evidence has accumulated that
inflammation is an important feature of athero-
sclerosis, both in the initiation phase and in the
advanced lesions where the complications of
atherothrombosis occur4,5,172. Inflammation has a
fundamental purpose in protecting the organism
from microbial and viral attacks and also plays a
key role in wound healing. Without inflammation
we would have no defence against infectious
diseases. However, the inflammatory process can
also be harmful. It has long been evident that even
a low grade of chronic inflammation could injure
the tissues, as is the case in well-known inflamma-
tory diseases, such as rheumatoid arthritis and
inflammatory bowel disease. Less obvious is the
harmful inflammation of the intima of the vascular
wall in atherosclerosis. In the initiation of athero-
sclerotic plaque formation, modified lipoproteins,
among other antigens, are thought to initiate an
inflammatory response. The modified, pre-
dominantly oxidized, LDL-particles activate the
endothelial cells, which in turn attract blood-
derived inflammatory cells into the intima.
As long as the phagocyting macrophages keep up
with the modified lipoproteins, the inflammation
is advantageous, but when the lipid burden is
growing, the inflammation aggravates and the
macrophages get overloaded with lipids and
become apoptotic. The formation of an athero-
sclerotic plaque begins and the inflammatory pro-
cess is maintained. Activated inflammatory cells
secrete cytokines that further aggravate the inflam-
mation and maintain the vicious circle. The
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inflammatory cytokines are suggested to promote
the weakening of the plaque’s fibrous cap partly
by reducing the proliferation of SMCs and their
secretion of procollagen, partly by enhancing the
production and activation of MMPs that are mainly
produced by macrophages9. SMCs are inhibited
by IFN-γ  and IL-1, and TNF-α is known to up-
regulate the transcription of MMPs, whereas TGF-
β decreases MMP transcription9,33,34. However, the
interaction between inflammatory cytokines and
MMPs is intricate and not yet fully understood.
In paper IV we investigated the inter-relationship
between a panel of inflammatory cytokines and
the proteases MMP-3 and MMP-1 in the SCARF
case-control study. All measurements were
performed in plasma or serum samples derived
from venous blood, i.e. reflecting the circulating
levels of cytokines and MMPs. The plasma levels
of IL-2, IL-6, IL-8 and TNF-α were significantly
elevated in the postinfarction patients. In addition,
there was a trend towards more patients with
detectable levels of IL-1β than controls, and the
detectable measurements were significantly higher
in patients than in controls. Also, as reported in
paper I, patients had higher hsCRP levels than
controls. These results indicate that a more active
inflammatory state prevails in patients than in
controls, as we presume that the inflammation
caused by the myocardial damage itself had
subsided at the time of blood sampling, three
months after the MI. These results extend those of
several previous smaller studies of separate cyto-
kines in relation to MI and CAD, as the SCARF
cohort is larger and all cytokines were analysed
simultaneously19,20,22. Also, the lack of difference
in IL-10 concentration between patients and
controls is in accordance with two earlier case-
control studies20,23, whereas another study has
shown higher IL-10 levels in CAD patients19.
The most interesting finding in paper IV is the
difference between MMP-3 and MMP-1 levels as
regards their respective correlations with several
inflammatory cytokines. The corollary is that the
expression of MMP-3 seems to be less influenced
by inflammation than the expression of MMP-1.
Recently, studies of different MMP-deficient apoE-
null mice have indicated divergent effects of
different MMPs in atherosclerosis43. In particular
MMP-3 was suggested to have atheroprotective
properties. The ApoE/MMP-3 double knockout
mice showed larger plaque area, fewer SMCs and
more buried fibrous layers, suggesting previous
plaque rupture, but there was no difference in
macrophage content of the intima as compared with
apoE single knockout mice43. This might be
interpreted that the atherosclerotic plaques have a
more vulnerable profile in the absence of MMP-3.
On the other hand, Silence et al. reported a lower
content of macrophages in the atherosclerotic
lesions of the apoE/MMP-3 double knockout mice
than in the apoE single knockout mice, indicating
less inflammation in the plaques of the double
knockout mice44.
In the pioneering work of Henney et al., MMP-3
gene expression was detected in atherosclerotic
plaques, both in macrophages and SMCs. How-
ever, the plaque that showed the most extensive
MMP-3 expression was lacking a lipid core39 and
presumably less inflamed. In addition, the in vitro
studies of Whatling et al. demonstrated that
activated macrophages increase their expression
of the MMP-1, MMP-2, MMP-9 and MMP-14
genes but, notably, not of MMP-337. Also, in a study
of carotid artery plaques, classified into four groups
according to histological features, the MMP-1
transcript levels were nearly eight-fold higher in
plaques with a thin cap as compared with plaques
featuring a thick cap, whereas there was only a
slight, and not statistically significant, increase
between those plaque groups in MMP-3 transcript
levels63.
Adhesion molecules are important in the initiation
of plaque formation as they promote adhesion and
attraction of inflammatory cells to the site of
activated endothelium. In a recent case-control
study of type 2 diabetes, there was an inverse
correlation between the concentrations of circu-
lating MMP-3 and soluble intercellular adhesion
molecule (sICAM-1) in diabetic subjects60. In
addition, the diabetic subjects had significantly
lower concentrations of MMP-3 than the control
subjects60, which is interesting as diabetic patients
are known to run an increased risk of cardiovascular
events. Devaraj et al. investigated whether a pro-
inflammatory phenotype could be identified by
hsCRP, comparing a number of proposed pro-
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inflammatory molecules between a group of
healthy individuals with high hsCRP (median level
3.7 mg/L) and a group of healthy individuals with
low hsCRP (median level 0.21 mg/L). Levels of
MMP-3 and MMP-9 were investigated, and the
two groups did not differ in MMP-3 concentration,
whereas the MMP-9 concentration was higher in
the high hsCRP group173. These recent studies
support the proposed hypothesis of a different
regulation of MMP-3 that is less influenced by
inflammation.
The most consistent evidence of inflammatory re-
gulation and involvement in plaque rupture exists
for MMP-9. Circulating plasma levels of MMP-9
predicted adverse outcome in a study of CAD
patients174. In addition, MMP-9 gene expression
was 10.8-fold higher in human macrophages than
in any other of 55 studied human tissues, using
DNA microarrays175. No other MMP genes were
among the 23 genes identified to have increased
expression in macrophages. In a study of carotid
artery plaques excised from patients undergoing
carotid endarterectomy, the plaque extract
concentrations of IL-6 and IL-8 were positively
correlated with those of MMP-2 and MMP-9176.
Also, the concentrations of IL-6, IL-8, MMP-2 and
MMP-9 were all higher in unstable carotid plaques
as compared with stable ones.
Ever since the work of Henney et al. and Galis et
al. in the mid 90’s38,39, which demonstrated that
several MMPs are present in atherosclerotic tissues,
the prevailing opinion has been that all MMPs
promote progression of atherosclerosis and, at least
partly, are the cause of plaque rupture by degrading
the fibrous cap. The notion of a uniform, destructive
role of MMPs in atherosclerosis is now being
questioned, and our results speak in favour of
reconsideration. Although preclinical studies of
MMP inhibitors have been promising in terms of
reducing remodelling and intimal hyperplasia, the
clinical trials conducted so far have been dis-
appointing as they could not reproduce the pre-
clinical findings177. Also, broad-spectrum MMP
inhibitors have been tested in clinical trials in the
cancer field, but failed success because of severe
side effects due to interference with normal tissue
function. The disappointing results of these clinical
studies reinforce the hypothesis of differential
effects of individual MMPs and emphasize the need
for more detailed knowledge about the role of
individual MMPs in atherosclerosis.
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CONCLUSIONS
 The circulating level of MMP-3 is markedly influenced by the MMP-3 -1612 5A/6A promoter
polymorphism.
 Reduced MMP-3 concentration seems to be associated with MI, whereas increased
concentration may promote progression of stable CAD.
 The MMP-3 concentration is clearly influenced by gender, being roughly two-fold higher in
men than in women. Similarly, the MMP-1 concentration seems to be lower in women.
 MMP-1 promoter polymorphisms influence the risk of MI.
 Inflammation is suggested to exert a stronger influence on the MMP-1 concentration than on
the MMP-3 concentration.
 The conclusions of this thesis reinforce the novel alternative hypothesis that different MMPs
have divergent effects on atherosclerosis and CAD.
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FUTURE PERSPECTIVES
 The roles of individual MMPs in atherosclerosis and CAD need to be investigated further
and better defined.
 The potential use of plasma concentrations of individual MMPs as predictors of CAD and
MI needs to be further evaluated in large prospective studies.
 Future studies of MMPs in CAD will require thorough definitions of different etiologies of
MI, presence of coronary stenosis, and stable versus vulnerable plaques.
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